atorvastatin has been researched along with Disease Models, Animal in 399 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.50) | 18.2507 |
| 2000's | 96 (24.06) | 29.6817 |
| 2010's | 256 (64.16) | 24.3611 |
| 2020's | 45 (11.28) | 2.80 |
| Authors | Studies |
|---|---|
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Mukhamejanova, Z; Pang, J; Tong, Y; Wen, T; Xiang, Q; Xu, F; Zhu, W | 1 |
| Ahmad Nazri, KA; Buang, F; Haji Mohd Saad, Q; Jantan, I; Jubri, Z; Mohd Fauzi, N | 1 |
| El-Hawwary, AA; Elmasry, A; Gaballah, A; Genedy, D; Ghayaty, E | 1 |
| Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q | 1 |
| Demos, C; Hu, S; Jo, H; Kang, DW; Kim, CW; Kumar, S; Perez, J; Sur, S; Xu, K; Yang, J | 1 |
| Fan, Y; Gao, C; Huang, J; Jiang, R; Liu, X; Ma, J; Wang, D; Wei, H; Yang, G; Zhang, J; Zhao, Z | 1 |
| Chen, T; Cui, M; Sui, Y; Yan, X; Yin, Y; Zhu, F | 1 |
| Chen, H; Chen, Z; Guo, J; Liu, H; Ma, Y; Peng, X; Wang, Q; Zheng, Z; Zhu, J | 1 |
| Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM | 1 |
| Deng, Y; Dong, L; He, Y; Li, F; Tang, Y; Tao, Z; Wen, S | 1 |
| Chen, M; Collu, R; Daley, S; Giunti, E; Xia, W | 1 |
| Goudarzi, F; Hashemnia, M; Mohammadalipour, A; Ravan, AP | 1 |
| Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY | 1 |
| Alenabi, A; Hallaj-Salahipour, M; Khoramjouy, M; Malekinejad, H; Malekinejad, M; Masoumi Verki, M | 1 |
| Baranowski, A; Förster, K; Hofmann, A; Klein, A; Mattyasovszky, SG; Mickan, T; Ritz, U; Rommens, PM; Schlemmer, L; Slotina, E; Truffel, S | 1 |
| Abu Elteen, K; Ajdidi, A; Kavanagh, K; Sheehan, G | 1 |
| Liu, ZL; Zeng, HT; Zhang, ZX; Zhao, M; Zhong, SM | 1 |
| Nie, W; Shi, K; Xie, D; Yu, B; Yu, M; Zhang, H | 1 |
| Cheng, XD; Jiang, H; Wang, YY | 1 |
| Chung, JH; Kang, SM; Lee, BS; Lee, CJ; Lee, SH; Lim, G; Lim, H; Oh, J; Park, S | 1 |
| Jimenez, VC; Norris, KA; Outwater, JA; Rabacal, W; Rayens, E; Schweitzer, F; Tarantelli, R; Whang, P | 1 |
| Chakrapani, LN; Kalaiselvi, P; Singh, A; Srinivasan, AK | 1 |
| Assali, M; Berus, JM; Ceneri, N; Choudhary, G; Christensen, JL; Dong, W; Healy, A; Lee, C; Mantsounga, C; Morrison, AR; Neverson, J; Nilson, R; Watts, JP; Wu, WC | 1 |
| Eser Faki, H; Tras, B; Uney, K | 1 |
| Chang, WL; Clapper, ML; Cooper, HS | 1 |
| Lin, D; Liu, J; Ma, D; Wei, C; Wu, A; Xiong, C; Yang, Y | 1 |
| Cao, GQ; Liu, H; Liu, JY; Tang, MM; Zhang, XQ; Zhu, YT | 1 |
| Alqahtani, S; Du, X; Ferreira, C; Franco, J; Kobos, LM; Shannahan, JH; Xia, L | 1 |
| Devasani, K; Kaul, R; Majumdar, A | 1 |
| Amput, P; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Palee, S; Pratchayasakul, W | 1 |
| Amorim, MES; de Freitas Araújo, MG; de Freitas Souza, T; de Oliveira Neto, AS; do Couto, RO; Fabri, RL; Rocha, VN; Souza, ILA | 1 |
| An, J; Dong, Z; Ge, J; Liu, G; Lu, Y; Ma, X; Shi, H; Sun, A; Wang, Y; Xian, X; Yu, Q | 1 |
| Choo, OS; Choung, YH; Gil, ES; Jang, JH; Kang, Y; Kim, YJ; Lee, YY | 1 |
| Bender, K; Bonaterra, GA; Kelber, O; Kinscherf, R; Metz, J; Metz, S; Schwarzbach, H; Weiser, D; Wilhelm, B | 1 |
| He, Y; Li, PB; Lin, QW; Liu, H; Su, WW; Wang, YG; Wu, H; Yan, ZH; Yao, HL; Zhang, WJ | 1 |
| Ahn, S; Ha, J; Min, SK; Oh, GT; Song, EJ | 1 |
| Gouda, T; Hara, H; Imai, T; Nakamura, S; Nishimura, Y; Saito, Y; Shimazawa, M | 1 |
| Askarian, F; Hekmatimoghaddam, S; Vahidi, F; Zabihi, M; Zabihi, MS | 1 |
| Bode, C; Boettler, T; Dederichs, TS; Dufner, B; Ehlert, CA; Härdtner, C; Heidt, T; Hilgendorf, I; Ho-Tin-Noé, B; Hoppe, N; Jander, A; Kaeser, R; Kohl, P; Kornemann, J; Krebs, K; Madl, J; Pieterman, EJ; Princen, HMG; Rauterberg, S; Robbins, CS; Sharipova, D; Stachon, P; Starz, C; Swirski, FK; von Zur Mühlen, C; Willecke, F; Wolf, D; Zirlik, A; Zou, J | 1 |
| Hüttl, M; Kazdová, L; Malínská, H; Marková, I; Miklánková, D; Oliyarnyk, O; Poruba, M; Rácová, Z; Večeřa, R | 1 |
| Brewer, AC; Bub, G; Carnicer, R; Casadei, B; Mighiu, AS; Recalde, A; Shah, AM; Simon, JN; Tomek, J; Verheule, S; Ziberna, K | 1 |
| Jiaqiong, L; Ming, L; Xiaoyong, L; Xinxue, L; Xuexian, T; Yan, L; Yinglan, L; Yue, G; Zena, H | 1 |
| Chen, J; Chen, Q; Li, M; Shi, Z; Wang, Y; Yan, T; Yang, L; Zhang, C | 1 |
| Abd El-Aal, RA; Abdel-Latif, HA; Abdelkader, NF; Abdulwahab, DK; Ibrahim, WW | 1 |
| Gao, G; Lian, G; Lin, T; Luo, L; Wang, H; Wu, J; Xie, L | 1 |
| El-Khashab, IH | 1 |
| Augustin, S; Barberá, A; Bravo, M; Estrella, F; Genescà, J; Gil, M; Hide, D; Martell, M; Raurell, I; Salcedo, MT | 1 |
| He, Z; Qi, P; Shen, F; Wang, Z; Xu, D; Zeng, F; Zhai, Z | 1 |
| Faistova, H; Faradonbeh, FA; Hroch, M; Hyspler, R; Igreja Sa, IC; Lastuvkova, H; Micuda, S; Mokry, J; Nachtigal, P; Nova, Z; Pavek, P; Schreiberova, J; Stefela, A | 1 |
| Chen, Y; Chen, YY; Cheng, HJ; Chiu, KY; Yuan, YT; Zeng, HQ; Zhang, XB | 1 |
| Akakpo, PK; Amoakohene, G; Antwi-Adjei, M; Biney, RP; Ekor, M; Henneh, IT; Obese, E; Owusu Agyei, PE; Yahaya, ES | 1 |
| Li, Y; Lu, G; Sun, D; Wang, DW; Yan, J; Zuo, H | 1 |
| Ahmed, S; Jamil, S; Khan, RA | 1 |
| Baalash, A; Ebeid, AM; Shafik, NM | 1 |
| Alves, V; Araujo, GRS; Carneiro, HCS; Costa, MC; de Resende Stoianoff, MA; Ferreira, GF; Fontes, ACL; Frases, S; Magalhães, TFF; Oliveira, LV; Paixão, TA; Ribeiro, NQ; Santos, DA; Santos, JRA | 1 |
| Hellberg, S; Jauhiainen, M; Knuuti, J; Liljenbäck, H; Metso, J; Nuutila, P; Roivainen, A; Saraste, A; Saukko, P; Savisto, N; Silvola, JMU; Sippola, S; Ståhle, M; Virta, J; Ylä-Herttuala, S | 1 |
| El-Nabarawi, N; El-Wakd, M; Salem, M | 1 |
| Fang, ZF; Guo, Y; Li, XP; Long, JK; Luo, F; Peng, DQ; Ruan, GY; Xia, Q; Zhao, SP; Zheng, XL | 1 |
| Li, J; Long, C; Peng, P; Wei, W | 1 |
| Huang, S; Su, B; Tao, Y; Yue, R; Zeng, J; Zeng, R; Zuo, C | 1 |
| Gao, H; Hu, Y; Li, X; Tian, R; Wang, Y; Williams, BR; Xu, P; Yan, F; Ying, L; Zhao, Y | 1 |
| Cheng, S; Gao, W; Jiang, R; Li, F; Sun, D; Wang, D; Wu, Y; Xu, X; Yin, D; Zhang, J; Zhang, Y; Zhou, S | 1 |
| Cunha Miranda, JV; de Azevedo Neto, E; de Oliveira Chaves, I; Dias, LDES; Dorsa Pontes, HB; Dourado, DM; Durães Gomes Oliva, JV; Kato da Silva, BA; Marques Dos Santos, CH; Martins de Almeida, MH; Sampaio, TL; Serra da Cruz Vendas, G | 1 |
| Cao, JT; Chen, K; Fan, YQ; Gao, L; Wang, CQ; Wang, Y; Xie, YS; Xu, ZJ; Yin, ZF; Zhang, HL | 1 |
| Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM | 1 |
| Canzian, JM; Duarte, MMMF; Duarte, T; Furian, AF; Grigoletto, J; Oliveira, CV; Oliveira, MS | 1 |
| Sun, J; Sun, Z; Yang, B; Yuan, Y | 1 |
| Ghasemi, A; Hamzeh, M; Hosseinimehr, SJ; Naeimi, RA; Talebpour Amiri, F | 1 |
| Ahmed, YM; Baothman, OAS; Khan, I; Khan, TJ; Mehanna, MG; Mohamed, SA; Yasir, M; Zamzami, MA | 1 |
| Auger, F; Barus, R; Bergeron, S; Bordet, R; Chen, Y; Cordonnier, C; Deguil, J; Durieux, N; Gautier, S; Pasquier, F; Potey, C; Ravasi, L; Skrobala, E | 1 |
| Chen, X; Niu, Y; Qin, L; Wang, Y | 1 |
| Afouna, MI; Ibrahim, EA; Ibrahim, HM; Zidan, MF | 1 |
| Fighera, MR; Furian, AF; Oliveira, CV; Oliveira, MS; Royes, LFF; Zorzi, VN | 1 |
| Archer, DR; Ataga, KI; Brown, LA; Chappa, P; Yin, H; Zahr, RS | 1 |
| Erdi, I; Kaya, B; Yasar, M | 1 |
| Barroso, MV; Cattani-Cavalieri, I; Gitirana, LB; Lanzetti, M; Melo, AC; Quesnot, N; Valença, SS | 1 |
| Liu, G; Yang, C; Yang, H; Yang, P; Yang, S; Zhao, D; Zheng, H | 1 |
| Cao, D; Gao, K; Li, Y; Peng, A; Qi, W; Tao, C; Wang, Y; Wu, Y | 1 |
| Allain, E; Allémann, E; Corpataux, JM; Delie, F; Haefliger, JA; Jordan, O; Meda, P; Mylonaki, I; Rougemont, AL; Saucy, F; Strano, F | 1 |
| Bacova, M; Bimbova, K; Fedorova, J; Galik, J; Jachova, J; Kisucka, A; Lukacova, N; Marsala, M; Papcunova, S; Pavel, J; Stropkovska, A; Zavacky, P | 1 |
| Beshah, E; Goldbaum, A; Jang, S; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Meng, H; Molokin, A; Solano-Aguilar, G; Stanley, J; Urban, JF; Walker, ME; Xie, Y | 1 |
| Akai, S; Matsubara, A; Oda, S; Tsuneyama, K; Yokoi, T | 1 |
| Cao, W; Cao, Z; Chen, X; Cheng, J; Gao, W; Guo, S; Jiang, Y; Li, B; Li, M; Li, Q; Li, X; Li, Z; Peng, C; Shen, J; Sun, J; Sun, X; Tian, F; Tian, Y; Tian, Z; Wang, H; Wang, P; Wang, T; Wang, W; Wang, Y; Yang, J; Yang, Y; Yao, J; Zhang, Z; Zhao, X; Zhou, Q | 1 |
| Chen, Y; Guo, Y; Jiang, XH; Li, YJ; Liu, SS; Ruan, CX; Wang, YJ; Weng, XG; Yang, Q; Zhou, BB; Zhu, XX | 1 |
| Chu, Y; Ding, M; Ma, H; Ren, H; Wang, C; Xu, Q; Yao, Q; Zuo, G | 1 |
| Dubois, L; Frisbee, JC; Frisbee, SJ; Lemaster, KA; Lewis, MT; Tzemos, N; Wiseman, RW; Wu, F | 1 |
| Amérand, A; Desfontis, JC; Didier, R; Farhat, F; Gilard, M; Mallem, MY; Mansourati, J; Moisan, C; Philouze, C; Pichavant-Rafini, K; Theron, M; Tissier, F | 1 |
| Devi Vemula, K; Mathur, M | 1 |
| Cheng, ZJ; Dai, TM; He, JL; Li, J; Shen, YY; Tu, JL | 1 |
| Liu, D; Nie, W; Shi, K; Xie, D; Yang, P; Yu, B; Zhang, H | 1 |
| Pan, H; Rui, R; Sun, B; Wang, X; Zhang, L | 1 |
| Aras, Y; Bagci-Onder, T; Erdag, E; Genc, C; Izgi, N; Tahta, A | 1 |
| Fang, H; Hu, J; Li, M | 1 |
| Abdel-Halim, M; Asimakopoulou, A; Hassan, R; Mansour, S; Safy, SE; Tammam, SN; Weiskirchen, R | 1 |
| Allan, SM; Badrock, AP; Barrington, J; Crilly, S; Fotiou, E; Hudson, G; Hurlstone, A; Kasher, PR; Laurie, SE; Njegic, A; Parry-Jones, AR; Rivers-Auty, J; Webb, K; Young, HL | 1 |
| Guo, J; Li, T; Liu, Y; Yao, Y; Zeng, Z; Zhang, R; Zhao, Y | 1 |
| Chen, W; Gao, G; Ge, L; Jiang, S; Sui, S; Zhai, C; Zhang, S | 1 |
| Batista, ML; Bedard, AH; Birbrair, A; Bueno, LL; Correa, VA; Farmer, SR; Franco, FO; Guilherme, A; Henriques, F; Knobl, P; Lopes, MA; Peres, SB; Santos, KB | 1 |
| Fang, T; Guo, B; Wang, L; Xue, L | 1 |
| Buss, ZS; Doneda, DL; Ferreira, YS; Fraga-Junior, EB; Lima, E; Lopes, L; Rios-Santos, F; Stupp, IJV; Taniguti, EH; Vandresen-Filho, S; Viola, GG | 1 |
| Dong, W; Jiang, R; Liang, W; Wang, Z; Wei, H; Yang, M; Yu, K; Zhang, J | 1 |
| Christodoulou, E; Kadoglou, NPE; Kakisis, J; Kostomitsopoulos, NG; Liapis, CD; Paronis, E; Stasinopoulou, M; Valsami, G | 1 |
| Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A | 1 |
| Chen, G; Cheng, K; Huang, P; Jin, C; Li, Q; Qian, H; Qian, L; Tian, X; Wang, L; Xiong, Y; Xu, J; Yang, Y; Yu, Y | 1 |
| Bolkent, S; Karatug Kacar, A; Oztay, F; Yildirim, M | 1 |
| Babu, PP; Kapadia, B; Mandaliya, D; Misra, P; Muggalla, CS; Patel, S; Prajapati, B; Rapaka, N; Saxena, U; Seshadri, S | 1 |
| Hu, MJ; Huang, PS; Jin, C; Li, Q; Liu, JD; Qian, L; Tian, XQ; Xiong, YY; Xu, J; Xu, JY; Yang, YJ | 1 |
| Chao, HC; Chiang, CS; Kuo, CH; Lee, TH; Tang, SC; Yang, SY | 1 |
| Ahsan, MZ; Bai, B; Han, X; Li, Y; Liu, G; Yuan, Y; Zhang, J; Zhang, S; Zhang, Y; Zhao, X | 1 |
| Feng, B; Li, PC; Wang, YR; Xu, L | 1 |
| Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P | 1 |
| Hu, JR; Lv, GH; Yin, BL | 1 |
| Castro, AA; Lapa, FR; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Viola, GG; Wiemes, BP | 1 |
| Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Briolant, S; Desgrouas, C; Dormoi, J; Pradines, B | 1 |
| Gierman, LM; Huizinga, TW; Kloppenburg, M; Koudijs, A; Kühnast, S; Pieterman, EJ; Princen, HM; Stojanovic-Susulic, V; van Osch, GJ; Zuurmond, AM | 1 |
| Anderson, L; Bond, V; Liu, M; Patrickson, J; Pitts, S; Solomon, W; Stiles, JK; Wilson, NO | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Bordet, R; Darteil, R; Duriez, P; Gautier, S; Hanf, R; Laprais, M; Ouk, T; Potey, C; Staels, B | 1 |
| Baxa, J; Boudová, L; Eberlová, L; Houdek, K; Kobr, J; Kočová, J; Křížková, V; Liška, V; Moláček, J; Nedorost, L; Tolinger, P; Tonar, Z; Třeška, V; Witter, K | 1 |
| Chen, C; Liu, T; Shen, DZ; Xin, SL | 1 |
| Dong, QT; Gao, RL; Geng, YJ; Gersh, BJ; He, ZX; Lu, MJ; Qian, HY; Qiao, SB; Shen, R; Song, L; Yang, YJ; Zhao, SH | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Chou, DW; Guo, H; Li, Q; Uitto, J | 1 |
| Bu, L; Cheng, Z; Dong, D; Huang, T; Shen, B; Tu, Y; Wan, L; Zhao, D | 1 |
| Balaganur, V; Kant, V; Kumar, D; Lingaraju, MC; More, AS; Pathak, NN; Tandan, SK | 2 |
| Do e, Z; Fukumoto, Y; Kanazawa, M; Matsumoto, Y; Sato, A; Satoh, K; Shimizu, T; Shimokawa, H; Takahashi, K | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Briolant, S; Desgrouas, C; Dormoi, J; Pascual, A; Pradines, B; Travaillé, C | 1 |
| Jiang, X; Qu, Z; Tian, Y; Xu, H | 1 |
| Abtahi Froushani, SM; Delirezh, N; Hobbenaghi, R; Mosayebi, G | 1 |
| Butte, AJ; De Vusser, K; Fischbein, MP; Gong, Y; Khatri, P; Kimura, N; Morgan, AA; Naesens, M; Robbins, RC; Roedder, S; Sarwal, MM | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Chen, Y; Huang, A; Ku, H; Li, LC; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Lloyd, DG; Ma, D; O'Dea, KP; Pac-Soo, C; Penn, JW; Takata, M; Vizcaychipi, MP; Wan, Y; Watts, HR | 1 |
| Abdallah, FR; Aldohmy, S; Elseweidy, MM; Kassem, HM; Younis, NN | 1 |
| Davoodpour, P; Larsson, L; Malm, J; Mörk, LM; Norata, GD; Parini, P; Rehnmark, S; Witt, MR | 1 |
| Ceron, CS; Gerlach, RF; Guimarães, DA; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y | 1 |
| Jaimes, EA; Raij, L; Tian, R; Zhou, MS | 1 |
| Lei, W; Li, H; Tian, J; Wu, K | 1 |
| Dunn, SE; Prod'homme, T; Steinman, L; Weber, MS; Youssef, S; Zamvil, SS | 1 |
| He, GX; Liu, XL; Xu, HP; Zhao, XJ | 1 |
| Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y | 1 |
| Aguirre, B; Alvarez-Gago, T; Bratos, MA; Cenizo Revuelta, N; Gonzalez-Fajardo, JA; Vaquero, C | 1 |
| Akahori, H; Eguchi, A; Hirotani, S; Iwasaku, T; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Sawada, H; Tsujino, T | 1 |
| Chen, J; Cui, W; Jiang, R; Li, T; Quan, W; Tian, Y; Wang, D; Wang, Y; Yu, H; Zhang, J; Zhou, L | 1 |
| Chen, J; Chen, S; Huang, H; Huang, Y; Liu, P; Liu, Z; Shen, X; Xu, S | 1 |
| Gul, M; Ozerol, E; Ozerol, IH; Parlakpinar, H; Simsek, Y; Yilmaz, E | 1 |
| Cardona-Gómez, GP; Garcia-Segura, LM; Gutierrez-Vargas, JA; Muñoz-Manco, JI | 1 |
| Guo, YQ; Li, YF; Shi, ST; Wang, ZH | 1 |
| Mokhtari-Dizaji, M; Rahmani-Cherati, T; Rostami, A; Vajhi, A | 1 |
| Deng, J; He, J; Hu, Z; Lei, Q; Liu, J; Lu, W; Song, T; Tao, X; Zhang, J; Zheng, L | 1 |
| Arévalo, M; Docherty, NG; Eleno, N; Fuentes-Calvo, I; Grande, MT; López-Novoa, JM; Pérez-Barriocanal, F; Rodríguez-Peña, AB | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Fang, Z; Huang, D; Li, X; Liu, Q; Xu, Y; Zheng, C; Zhou, S | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Ashrafi, A | 1 |
| Chang, YP; Mitchell, BD; Montasser, ME; O'Hare, EA; Wang, X; Zaghloul, NA | 1 |
| Bianchi, C; Chu, LM; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Ai, R; Chen, F; Li, G; Lu, WH; Tang, ZZ; Wu, XW | 1 |
| Boiati, RF; dos Santos Batista, JG; Jacobsen, O; Manchini, MT; Nascimento, JW; Silva Júnior, JA | 1 |
| Abdallah, MA; Asker, Mel-S; Atteia, HH; El-Seweidy, MM; Eldahmy, SI | 1 |
| Caglayan, AB; Caglayan, B; Demirci, S; Dogan, A; Ekimci, N; Ethemoglu, MS; Kilic, E; Kilic, U; Oztezcan, S; Sahin, F; Seker, FB; Yilmaz, B | 1 |
| Karpe, PA; Kumar, S; Malek, V; Patel, G; Sanghavi, M; Srinivasan, K; Tikoo, K | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Guan, Y; Guo, HY; Shan, ZL; Wang, YT; Yuan, HT; Zhang, Y | 1 |
| Deng, JG; Liu, J; Song, T; Tao, X | 1 |
| Abd Elmaaboud, MA; Albarraq, AA; Kabel, AM | 1 |
| Cui, W; Gao, H; Hu, H; Li, B; Li, X; Wang, Y; Zhang, H; Zhao, Z | 1 |
| Alpay, MF; Cakir, O; Colak, N; Nazli, Y; Uysal, S; Uzunlar, AK | 1 |
| Cui, L; Fu, Z; Huang, J; Lee, WY; Li, G; Liang, Y; Lin, S; Qin, L; Sun, Y; Wu, H; Wu, T; Xu, L | 1 |
| Choudhury, S; Darzi, SA; Dash, JR; Debroy, B; Kannan, K; Mishra, SK; Parida, S; Paul, A; Pule Addison, M; Singh, TU; Singh, V; Thangamalai, R | 1 |
| Chen, JY; Chu, LW; Wu, BN; Wu, PC | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Ahmadi, A; Baradaran, A; Hasanpour, Z; Nasri, H; Nasri, P; Nematbakhsh, M; Rafieian-Kopaei, M | 1 |
| Deng, L; Gong, L; Li, D; Li, Y; Qi, C; Wu, W; Zhang, C; Zhang, Q; Zhang, T; Zhang, Y | 1 |
| Hanlin, S; Kexuan, T; Ming, Y; Yuliang, W; Zejian, W | 1 |
| Abdel-Hamid, AA; Firgany, Ael-D | 1 |
| Callies, S; Demmer, P; Hu, N; Janssen, H; Larmann, J; Loghmani-khouzani, H; Schuett, H; Sölter, G; Theilmeier, G; Tietge, UJ; Wagner, CS; Warnecke, G | 1 |
| Deng, Y; Guo, XL; Liu, HG; Pan, YY; Yuan, X; Zhu, D | 1 |
| Capel, F; Chabrier, G; Cynober, L; de Bandt, JP; Durand, C; Jouve, C; Le Plenier, S; Moinard, C; Morio, B; Pitois, E; Rigaudière, JP | 1 |
| Kaleağasıoğlu, F; Olcay, E; Olgaç, V | 1 |
| Duan, RS; Li, H; Li, XL; Li, YB; Liu, Y; Miao, S; Wang, CC; Wang, S; Yue, LT; Zhang, M; Zhang, P | 1 |
| Li, L; Liu, T; Liu, Y; Su, Q; Wang, J; Zhou, Y | 1 |
| Ceron, CS; Gerlach, RF; Guimarães, DA; Martins-Oliveira, A; Rizzi, E; Shiva, S; Tanus-Santos, JE | 1 |
| Bian, B; Nie, J; Teng, T; Wang, Q; Yu, X | 1 |
| de Oliveira, RM; Ferreira, ED; Godinho, J; Milani, H; Previdelli, IS; Ribeiro, MH; Zaghi, GG | 1 |
| Hou, T; Lee, SM; Li, C; Li, D; Li, Y; Pan, P; Shen, M; Sun, H; Tian, S; Zhou, H | 1 |
| Lee, CR; Zeldin, DC | 1 |
| Chen, H; Dai, G; Deng, Y; Gao, J; Li, Y; Luo, R; Wang, Y; Wu, X; Xu, Q; Yuan, W | 1 |
| Chen, H; Li, L; Liu, T; Su, Q; Wang, J; Wang, XT; Zhou, Y | 1 |
| Fatar, M; Grudzenski, S; Heiler, P; Hennerici, MG; Reuter, B; Schad, L; Staufenbiel, M; Venus, A | 1 |
| De Meyer, GR; Martinet, W; Rombouts, M; Roth, L; Schrijvers, DM | 1 |
| Chen, L; Chen, T; Li, G; Wan, Q; Wang, C; Yin, J; Zhao, L; Zhi, W | 1 |
| Fujii, Y; Kasahara, R; Ohora, K; Ono, Y; Sobue, K; Suzuki, K; Tanida, M; Yamamoto, N | 1 |
| Amuzie, C; Denham, S; Mais, DE; Rogers, CS; Swart, JR; Vihtelic, T | 1 |
| Debus, S; Eschrich, J; Hecker, M; Korff, T; Kuk, H; Meyer, R; Noppeney, T; Wagner, AH | 1 |
| Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X | 1 |
| Chen, J; Jiang, R; Li, T; Tian, Y; Wang, D; Wang, L; Wang, Y; Wei, H; Yang, G; Yu, S; Zhang, JN; Zhang, Y; Zhao, Z | 1 |
| Wang, M; Wang, Y; Zhao, C; Zhao, M | 1 |
| Cerne, D; Drevensek, G; Janic, M; Jerin, A; Lunder, M; Marc, J; Sabovic, M; Skitek, M | 1 |
| Crevar-Sakac, M; Ivanisević, J; Jelić-Ivanović, Z; Kotur-Stevuljević, J; Markelić, M; Milenković, M; Vujcić, Z; Vujić, Z | 1 |
| Cheng, W; Hu, H; Li, X; Shi, Y; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J | 1 |
| Aubry, T; Bourgeois, N; Desfontis, JC; Didier, R; Dubreuil, M; Gilard, M; Goanvec, C; Le Grand, Y; Mallem, Y; Mansourati, J; Pichavant-Rafini, K; Plee-Gautier, E; Roquefort, P; Theron, M; Tissier, F | 1 |
| Cui, L; Li, F; Wang, J; Yang, F | 1 |
| Dang, Y; Hao, X; Li, Y; Qi, X; Song, X; Yang, Q | 1 |
| Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM | 1 |
| Amini-Khoei, H; Dehpour, A; Hassanipour, M; Imran-Khan, M; Rahimi, N; Rezayat, SM; Shafaroodi, H; Shirzadian, A | 1 |
| Ambadipudi, K; Cui, MH; Jelicks, LA; Lizardo, K; Lora, J; Nagajyothi, JF; Zhao, D | 1 |
| Dong, J; Liao, L; Liu, F; Liu, J; Mou, Y; Shen, X; Yang, T; Zhou, X | 1 |
| Binder, LB; Constantino, LC; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zomkowski, A | 1 |
| El Desoky, ES; Fadil, SA; Hassan, AKM; Salem, SY; Taha, AF | 1 |
| Cardona-Gómez, GP; Guarin, CJ; Gutierrez-Vargas, J; Hernández, PA; Rodríguez-Perea, AL; Rojas, M | 1 |
| Hua, BJ; Li, HY; Liu, ZQ; Su, YY; Zhang, YF | 1 |
| Cheng, WP; Chua, SK; Lo, HM; Lu, MJ; Shyu, KG; Wang, BW | 1 |
| Bgatova, NP; Goncharova, NV; Johnston, TP; Khrapova, MV; Korolenko, E; Korolenko, T; Lykov, AP; Machova, E; Nescakova, Z; Sakhno, LV; Shintyapina, AB | 1 |
| Carvalho Sposito, A; da Mota Silveira-Filho, L; de Souza Vilarinho, KA; Diógenes de Carvalho, D; Galluce Torina, A; Martins de Oliveira, PP; Pereira do Carmo, HR; Petrucci, O; Reichert, K | 1 |
| Li, HY; Li, YQ; Su, YY; Wang, JL; Wang, Q; Yang, S; Zhang, YF | 1 |
| Amin, B; Mohebbi, E; Nazemi, S; Pajohanfar, NS; Pejhan, A; Rad, A | 1 |
| Graham, KL; Higgins, JP; Ho, PP; Lee, LY; Steinman, L; Utz, PJ | 1 |
| Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT | 1 |
| Lee, JK; Singh, AK; Singh, I; Won, JS | 1 |
| Kim, YH; Kim, YJ; Lee, SH; Yoon, BW | 1 |
| Beskonakl i, E; Bodur, E; Eroglu, H; Gurcan, O; Okutan, O; Oner, L; Sargon, MF; Turkoglu, OF | 1 |
| Momohara, C; Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I | 1 |
| Abraldes, JG; Arroyo, V; Bataller, R; Colmenero, J; Dominguez, M; Egido, J; Ginès, P; Moreno, M; Ramalho, F; Ramalho, LN; Ruiz-Ortega, M; Sancho-Bru, P | 1 |
| Chavalmane, AK; Fibbi, B; Filippi, S; Forti, G; Maggi, M; Morelli, A; Sarchielli, E; Silvestrini, E; Vannelli, GB; Vignozzi, L; Zhang, XH | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE | 1 |
| Satoh, A; Satoh, M | 1 |
| Anthony, FW; Curzen, NP; Hanson, MA; Hopkins, LA; Kelsall, CJ; Torrens, C | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Gryglewski, R; Hassan, M; Heeba, G; Khalifa, M; Malinski, T; Moselhy, ME | 1 |
| Ajith, TA; Anu, V; Riji, T | 1 |
| Li, JJ; Li, XY; Li, Y; Qin, L; Yang, P | 1 |
| Caruthers, SD; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Daghini, E; Del Tacca, M; Duranti, E; Fornai, M; Ghisu, N; Giannarelli, C; Taddei, S; Versari, D; Virdis, A | 1 |
| Boyle, A; Connelly, KA; Gilbert, RE; Kelly, D; Kompa, A; Krum, H; Martin, JH; Zhang, Y | 1 |
| Ghante, MH; Ghule, BV; Saoji, AN; Yeole, PG | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Boeck, CR; Carqueja, CL; Dal'agnolo, D; de Araújo Herculano, B; Martins, WC; Piermartiri, TC; Stroeh, E; Tasca, CI; Vandresen-Filho, S | 1 |
| Chen, YX; Fu, Y; Kong, MY; Nie, RQ; Wang, JF; Wang, XQ; Yao, YJ | 1 |
| Finlay, GA; Kwiatkowski, DJ; Malhowski, AJ; Malinowska-Kolodziej, I; Polizzi, K | 1 |
| Chopp, M; Cui, Y; Jia, L; Lu, M; Zhang, L; Zhang, ZG | 1 |
| Chopp, M; Han, Y; Karki, K; Knight, RA; Ledbetter, KA; Seyfried, DM; Yang, D; Zhang, J | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Fang, Y; Li, X; Lin, J; Ren, L; Wang, X; Yin, Z; Zhang, A | 1 |
| Kathirvel, K; Kuntamallappanavar, G; Leo, MD; Mishra, SK; Subramani, J; Uttam Singh, T | 1 |
| Aigbirhio, FI; Bird, JL; Davenport, AP; Davies, JR; Figg, N; Fryer, TD; Izquierdo-Garcia, D; Richards, HK; Rudd, JH; Warburton, EA; Weissberg, PL | 1 |
| He, CC; He, WK; Liang, LY; Luo, BH; Su, CJ; Zeng, ZH; Zhang, ZH | 1 |
| Andrade, SP; Araújo, FA; Mendes, JB; Rocha, MA | 1 |
| Aikawa, E; Figueiredo, JL; Hembrador, S; Keliher, E; Kelly, K; Libby, P; Nahrendorf, M; Panizzi, P; Weissleder, R; Zhang, H | 1 |
| Cekmen, M; Ilbey, YO; Ozbek, E; Polat, EC; Simsek, A; Somay, A | 1 |
| Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S | 1 |
| Hillyer, J; Kwon, BK; Lee, JH; Mann, CM; Stammers, AM; Tetzlaff, W | 1 |
| Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 1 |
| Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N | 1 |
| Aksakal, O; Aksoy, Y; Gungor, T; Kilic, S; Lordlar, N; Ozat, M; Sut, N; Yilmaz, B | 1 |
| Carpentino, JE; Eaton, K; Higgins, PD; Huang, EH; Hynes, MJ; Johnson, LA | 1 |
| Liang, Y; Shen, F; Wang, A; Wang, J | 1 |
| Chen, J; Ge, S; Liu, D; Liu, X; Xu, G; Yin, Q; Zhang, R; Zhou, G; Zhu, W | 1 |
| Cadirci, E; Coskun, K; Halici, Z; Kilic, C; Nuri Keles, O; Odabasoglu, F; Oral, A; Suleyman, H; Unal, B | 1 |
| Chen, L; Ding, G; Jia, R; Tu, Y | 1 |
| Chang, CZ; Howng, SL; Hwang, SL; Kwan, AL; Lin, CL; Wu, SC | 1 |
| Aydin, NE; Elmali, N; Esenkaya, I; Sakarya, B; Unay, K | 1 |
| Belgamwar, V; Maurya, D; Tekade, A | 1 |
| Aboosaeedi, HR; Eskandari, M; Eskandary, H; Karamouzian, S; Malekpoor-Afshar, R; Reihani-Kermani, H; Saeed, A; Safizade, H | 1 |
| Li, L; Sun, TW; Wang, LX; Zhang, JY | 1 |
| Lin, P; Xie, H; Xie, L; Xu, C | 1 |
| Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L | 1 |
| Bando, YK; Monji, A; Morimoto, Y; Murohara, T; Shigeta, T | 1 |
| Biessen, EA; Bot, I; Jukema, JW; Lankhuizen, IM; van Berkel, TJ | 1 |
| Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Martin, S; Murphy, MP; Sultana, R | 1 |
| Goes, P; Lima, AP; Lima, V; Melo, IM; Rêgo, RO | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Hagita, S; Osaka, M; Shimokado, K; Yoshida, M | 1 |
| Hirata, Y; Sata, M | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Dong, Y; Li, ZH; Wei, LQ | 1 |
| Dehpour, AR; Fakhraei, N; Javadi-Paydar, M; Mirazi, N; Norouzi, A; Rayatnia, F; Zakeri, M | 1 |
| Blankier, S; Ito, S; McCrindle, BW; Yeung, RS | 1 |
| Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 3 |
| Aktunc, E; Arasli, M; Barut, F; Gun, BD; Kayhan, B | 1 |
| Al Nuaimi, H; Al-Ani, B; Savage, C | 1 |
| Eick, C; Laszlo, R; Menzel, KA; Schreieck, J; Schreiner, B; Schwiebert, M | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Aronica, E; Gorter, JA; Holtman, L; Schmitz, LJ; van Vliet, EA; Wadman, WJ | 1 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Chen, ZY; Lei, L; Li, LY; Liu, Q; Liu, SN; Shen, ZF; Zhang, N | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Aguilar, C; Rodríguez-Delfín, L; Ventura, F | 1 |
| Garcia, GG; Miranda, HF; Noriega, V; Olavarría, L; Prieto, JC; Sierralta, F; Zepeda, RJ | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Korkor, MT; Liu, B; Liu, JY; Song, XJ; Wei, Q; Yang, CY; Yang, P | 1 |
| Cai, A; Dai, G; Dong, Y; Huang, Y; Jiang, Z; Kuang, J; Liao, X; Mai, W; Qiu, R; Rao, S; Song, Y; Zheng, D | 1 |
| Daemen, MJ; Gabriels, K; Gijbels, MJ; Heeneman, S; Hoving, S; Pol, JF; Russell, NS; Stewart, FA; te Poele, JA | 1 |
| Cui, JJ; Gao, F; Li, YR; Wang, D | 1 |
| Czuczwar, SJ; Luszczki, JJ; Stepien, KM; Tomaszewski, M | 1 |
| Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Mosnier, J; Pradines, B; Rogier, C; Savini, H; Soulard, R; Souraud, JB | 1 |
| Du, Y; Ji, H; Li, L; Li, S; Liu, H; Zhang, X | 1 |
| Gradosova, I; Hubena, S; Palicka, V; Svejkovska, K; Zivna, H; Zivny, P | 1 |
| Cherkanova, MS; Filjushina, EE; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA | 1 |
| Alberti, PF; Conti, V; Corazzi, T; Falcinelli, E; Gresele, P; Miglietta, D; Minuz, P; Momi, S; Monopoli, A; Ongini, E | 1 |
| Dehpour, AR; Fakhrzad, A; Hassanipour, M; Hassanpour, S; Moezi, L; Shafaroodi, H | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| Chang, XR; Fu, L; He, XQ; Liu, M; Shang, LC; Yu, BS; Yuan, JL; Yue, ZH; Zhang, L | 1 |
| Cao, H; Cui, W; Du, B; Lin, S; Liu, Y; Qin, L; Xu, G | 1 |
| Drevenšek, G; Janić, M; Jerin, A; Lunder, M; Sabovič, M; Skitek, M; Ziberna, L | 1 |
| Guan, F; Ju, J; Li, G; Liu, AB; Sun, Y; Yang, CS; Yang, Z | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Dehpour, AR; Fakhrzad, A; Hassanipour, M; Moezi, L; Rezayat, M; Shafaroodi, H | 1 |
| Bosch, J; García-Cardeña, G; García-Pagán, JC; Gracia-Sancho, J; Hide, D; Marrone, G; Rosado, E; Russo, L | 1 |
| Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW | 1 |
| Cho, HJ; Kim, HS; Kim, SJ; Kwon, YW; Lee, HY; Lee, SW; Oh, BH; Park, YB; Youn, SW | 1 |
| Chaogang, T; Ewen, T; Guanghong, X; Jun, W; Liming, T; Qiuting, L; Tao, T | 1 |
| Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S | 1 |
| Frank, J; Grebenstein, N; Hofmann, U; Podszun, MC | 1 |
| Aeed, H; Bruck, R; Gavish, D; Sharvit, E; Shirin, H | 1 |
| Fan, YC; Li, XH; Wang, D; Wang, M; Zhang, YY | 1 |
| Guo, R; Heng, X; Liang, X; Shi, Y; Yang, L; Zhou, X | 1 |
| Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G | 1 |
| Bell, RM; Yellon, DM | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Amano, Y; Imura, Y; Ishikawa, E; Nishimoto, T; Sugiyama, Y; Tozawa, Ri | 1 |
| Bao, Y; Bernard, SA; Lazar, HL; Zhang, Y | 1 |
| Ichihara, K; Kanda, M; Satoh, K | 1 |
| Chen, J; Chopp, M; Goussev, A; Li, Y; Lu, D; Mahmood, A; Pannu, P | 1 |
| Bydon, A; Chen, J; Chopp, M; Han, Y; Lu, D; Seyfried, D | 1 |
| Rajamannan, NM | 1 |
| Busso, N; Chobaz, V; Gabay, C; Palmer, G; So, A; Talabot-Ayer, D; Taylor, S | 1 |
| Barbosa, E; Pannu, R; Singh, AK; Singh, I | 1 |
| Chopp, M; Goussev, A; Lu, D; Mahmood, A; Qu, C; Zhang, ZG | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Nagano, I; Nagotani, S; Sato, K; Shoji, M; Zhang, W | 1 |
| Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Chen, SN; Halder, T; Marian, AJ; Nagueh, SF; Roberts, R; Senthil, V; Tsybouleva, N; Willerson, JT | 1 |
| Deng, P; Hong, SC; Wu, J; Wu, ZH; Zhao, SP | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A | 1 |
| Gao, C; Li, WM; Liu, W; Zhou, BG | 1 |
| Bradbury, J | 1 |
| Chen, AF; Hong, H; Kaufman, DI; Kreulen, DL; Zeng, JS | 1 |
| Huang, TG; Mondo, CK; Su, JZ; Yang, WS | 1 |
| Arcas, I; Ayala, I; Castells, MT; Corral, J; García-Pérez, B; Hernández-Espinosa, D; Martín-Castillo, A; Miñano, A; Vicente, V | 1 |
| Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE | 1 |
| Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Almog, Y; Avnon, LS | 1 |
| Chen, L; Huang, J; Qian, H; Shen, D; Tang, Q; Wang, H; Wang, T; Wu, H; Xiong, R | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Bayraktar, N; Eroglu, D; Esinler, I; Haberal, N; Oktem, M; Zeyneloglu, HB | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Lui, CY; Martinez, JD; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Itaya, M; Ogura, Y; Sakurai, E; Yamada, K; Yamasaki, S | 1 |
| Guyton, JR; Laskowitz, DT; Lynch, JR; Mace, B; Song, P; Wang, H; Warner, DS; Yang, HJ; Yates, RB | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Chopp, M; Hozeska-Solgot, A; Liu, XS; Zhang, L; Zhang, ZG | 1 |
| Méndez-Sánchez, N; Uribe, M; Zamora-Valdés, D | 1 |
| Chu, K; Han, Z; Hong, NH; Im, WS; Jung, KH; Kang, L; Kim, M; Kim, MW; Lee, ST; Park, JE | 1 |
| Date, AA; Nagarsenker, MS | 1 |
| Bauersachs, J; Brandt, M; Closs, E; Daiber, A; Ertl, G; Förstermann, U; Münzel, T; Oelze, M; Thum, T; Wenzel, P; Xu, J; Zou, MH | 1 |
| Chen, J; Chopp, M; Cui, X; Li, A; Lu, M; Roberts, C; Zacharek, A | 1 |
| Chen, M; Liu, B; Ou, ST; Peng, HX; Zhang, C | 1 |
| Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV | 1 |
| Kanagarajan, N; Murthy, S; Nam, JH; Noah, ZA | 1 |
| Chen, MH; Liu, JH; Zhou, Y | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Andrys, C; Jamborova, G; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y | 1 |
| Gao, Y; Ge, GY; Jia, YJ; Jiang, MN; Song, LX | 1 |
| Abu Said, GH; Birnbaum, Y; Hughes, MG; Lin, Y; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Ye, Y | 1 |
| Aprigliano, I; Dudas, J; Ramadori, G; Saile, B | 1 |
| Ebdrup, L; Granfeldt, A; Hokland, M; Krog, J; Larsen, PØ; Tønnesen, E; Vestergaard, C | 1 |
| Arnold, M; Daniel, WG; Garlichs, CD; Petzi, S; Raaz, D; Seybold, K; Stumpf, C; Wasmeier, G; Yilmaz, A | 1 |
| Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Aoki, M; Miyake, T; Morishita, R; Nishimura, M; Ogihara, T; Ohgi, S; Shiraya, S; Yoshikazu, F | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortega, L; Ortego, M; Pérez, F; Tuñón, J | 1 |
| Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF | 1 |
| Baker, JC; Emeson, EE; Hall, D; Jamal, S; Johnston, TP; Palmer, WK | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
| Aparicio, C; Blanco-Colio, LM; Díaz, C; Egido, J; Gerique, JG; Gómez-Hernández, A; Hernández, G; Hernández-Presa, MA; Hernández-Vargas, P; Martín-Ventura, JL; Mas, S; Ortega, L; Ortego, M; Tuñón, J; Vivanco, F | 1 |
| Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, M; Tanaka, H; Yasuda, S | 1 |
| Adeli, K; Cheung, RC; Mangaloglu, L; Pontrelli, L; Taghibiglou, C; Van Iderstine, SC | 1 |
| Bonow, RO; McConnell, JP; Niekrasz, M; Rajamannan, NM; Sebo, TC; Singh, RJ; Spelsberg, TC; Springett, M; Stone, NJ; Subramaniam, M | 1 |
3 review(s) available for atorvastatin and Disease Models, Animal
| Article | Year |
|---|---|
Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Topics: Aberrant Crypt Foci; Adenoma; Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents; Aspirin; Atorvastatin; Carcinogenesis; Catechin; Clinical Trials as Topic; Colon; Colonoscopy; Colorectal Neoplasms; Dietary Supplements; Disease Models, Animal; Humans; Intestinal Mucosa; Lycopene; Mice; Mutation; Treatment Outcome | 2020 |
Atorvastatin treatment improves effects of implanted mesenchymal stem cells: meta-analysis of animal models with acute myocardial infarction.
Topics: Animals; Atorvastatin; Chi-Square Distribution; Combined Modality Therapy; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Recovery of Function; Regeneration; Stroke Volume; Time Factors; Ventricular Function, Left | 2015 |
The pressure is rising.
Topics: Animals; Atorvastatin; Critical Care; Disease Models, Animal; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Pulmonary Embolism; Pyrroles; Rats | 2007 |
1 trial(s) available for atorvastatin and Disease Models, Animal
| Article | Year |
|---|---|
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
395 other study(ies) available for atorvastatin and Disease Models, Animal
| Article | Year |
|---|---|
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR alpha; Proteomics; Pyrans; Signal Transduction | 2022 |
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Atorvastatin; Blood Pressure; Carotid Intima-Media Thickness; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Female; Inflammation; Plant Extracts; Postmenopause; Rats; Rats, Sprague-Dawley; Vasoconstriction; Vasodilation | 2021 |
Standardized study of atorvastatin possible osteoarthritis disease-modifying effect in a rat model of osteoarthritis.
Topics: Animals; Atorvastatin; Carrageenan; Disease Models, Animal; Male; Osteoarthritis; Plant Extracts; Rats; Rats, Sprague-Dawley | 2022 |
Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Calcium; Disease Models, Animal; Fluorine Radioisotopes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Rabbits; Radiopharmaceuticals; Sodium Fluoride; Vascular Calcification | 2021 |
Atorvastatin and blood flow regulate expression of distinctive sets of genes in mouse carotid artery endothelium.
Topics: Animals; Atorvastatin; Carotid Arteries; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Male; Mice; Mice, Inbred C57BL | 2021 |
Atorvastatin combined with dexamethasone promote hematoma absorption in an optimized rat model of chronic subdural hematoma.
Topics: Animals; Atorvastatin; Cytokines; Dexamethasone; Disease Models, Animal; Hematoma, Subdural, Chronic; Inflammation; Neovascularization, Physiologic; Rats | 2021 |
Influence of Gegenqinlian Decoction on Pharmacokinetics and Pharmacodynamics of Atorvastatin Calcium in Hyperlipidemic Rats.
Topics: Animals; Area Under Curve; Atorvastatin; Disease Models, Animal; Drugs, Chinese Herbal; Herb-Drug Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Random Allocation; Rats; Rats, Sprague-Dawley | 2022 |
Atorvastatin-induced tolerogenic dendritic cells improve cardiac remodeling by suppressing TLR-4/NF-κB activation after myocardial infarction.
Topics: Animals; Apoptosis; Atorvastatin; Cytokines; Dendritic Cells; Disease Models, Animal; Fibrosis; Mice; Myocardial Infarction; Myocardium; Myocytes, Cardiac; NF-kappa B; Stroke Volume; Toll-Like Receptor 4; Ventricular Function, Left; Ventricular Remodeling | 2023 |
IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model.
Topics: Animals; Atorvastatin; Cartilage; Cholesterol; Disease Models, Animal; Dyslipidemias; Female; Inflammation; Mice; Osteoarthritis; Proprotein Convertase 9; Synovitis | 2023 |
Atorvastatin attenuates allergic inflammation by blocking prostaglandin biosynthesis in rats with allergic rhinitis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cytokines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Inbred BALB C; Nasal Mucosa; NF-kappa B; Ovalbumin; Prostaglandins; Rats; Rhinitis, Allergic | 2023 |
Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau mice.
Topics: Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Mice; Mice, Transgenic; Proteomics; tau Proteins | 2023 |
Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis.
Topics: Animals; Atorvastatin; Carbon Tetrachloride; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Hepatic Stellate Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome | 2019 |
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53 | 2019 |
Cardioprotective Effects of Atorvastatin Are Mediated Through PPARγ in Paraquat-Exposed Rats.
Topics: Animals; Antioxidants; Atorvastatin; Cardiotoxicity; Creatine Kinase, MB Form; Cyclooxygenase 2; Disease Models, Animal; Heart Diseases; Lipid Peroxidation; Male; Myocytes, Cardiac; Nitric Oxide; Oxidative Stress; Paraquat; Peroxidase; PPAR gamma; Rats, Wistar; Signal Transduction; Sulfhydryl Compounds | 2019 |
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; Losartan; Male; Rats; Rats, Sprague-Dawley | 2019 |
Assessment of the
Topics: Animals; Antifungal Agents; Atorvastatin; Candida albicans; Candidiasis; Disease Models, Animal; Drug Evaluation, Preclinical; Fungal Proteins; Humans; Larva; Moths | 2019 |
Atorvastatin improves the cardiac function of rats after acute myocardial infarction through ERK1/2 pathway.
Topics: Acute Disease; Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Echocardiography; Heart Function Tests; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Rats; Rats, Sprague-Dawley | 2019 |
Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity.
Topics: Animals; Aorta; Atorvastatin; Collagen; Constriction, Pathologic; Disease Models, Animal; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; MicroRNAs; Myocardium; Rats; Smad2 Protein; Transforming Growth Factor beta1; Ventricular Remodeling | 2020 |
Effect of atorvastatin on pulmonary arterial hypertension in rats through PI3K/AKT signaling pathway.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Signal Transduction; Up-Regulation | 2019 |
Atorvastatin protects cardiomyocyte from doxorubicin toxicity by modulating survivin expression through FOXO1 inhibition.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Cell Line; Cell Nucleus; Cytoprotection; Disease Models, Animal; Doxorubicin; Forkhead Box Protein O1; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Sp1 Transcription Factor; Survivin; Transcription, Genetic; Transcriptional Activation | 2020 |
Statin treatment prevents the development of pulmonary arterial hypertension in a nonhuman primate model of HIV-associated PAH.
Topics: Animals; Atorvastatin; Disease Models, Animal; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macaca mulatta; Macrophages, Alveolar; Monocytes; Pulmonary Arterial Hypertension; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Viral Load | 2019 |
LOX-1, the Common Therapeutic Target in Hypercholesterolemia: A New Perspective of Antiatherosclerotic Action of Aegeline.
Topics: Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cell Line; Diet, High-Fat; Disease Models, Animal; Humans; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Mice; Molecular Targeted Therapy; Rats; Rats, Wistar; Scavenger Receptors, Class E | 2019 |
Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification.
Topics: Aged; Animals; Atherosclerosis; Atorvastatin; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Macrophages; Male; Mice, Knockout, ApoE; Neuropeptides; Plaque, Atherosclerotic; Prenylation; rac1 GTP-Binding Protein; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Retrospective Studies; rho Guanine Nucleotide Dissociation Inhibitor alpha; Signal Transduction; Vascular Calcification | 2020 |
Alpha lipoic acid and vitamin E improve atorvastatin-induced mitochondrial dysfunctions in rats.
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Atorvastatin; Case-Control Studies; Disease Models, Animal; Kidney; Male; Mitochondria; Mitochondria, Heart; Mitochondria, Liver; Rats; Rats, Wistar; Thioctic Acid; Treatment Outcome; Vitamin E | 2020 |
Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Postoperative Cognitive Complications; PPAR gamma; Signal Transduction | 2020 |
Effect of atorvastatin on pulmonary hypertension rats through regulating notch signaling pathway.
Topics: Administration, Oral; Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Hypertension, Pulmonary; Male; Rats; Rats, Sprague-Dawley; Receptor, Notch1; Signal Transduction | 2020 |
Exacerbation of Nanoparticle-Induced Acute Pulmonary Inflammation in a Mouse Model of Metabolic Syndrome.
Topics: Animals; Atorvastatin; Diet, High-Fat; Diet, Western; Disease Models, Animal; Disease Susceptibility; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Metabolic Syndrome; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Pneumonia; Real-Time Polymerase Chain Reaction; RNA, Messenger; Silver; Treatment Outcome | 2020 |
Supplementation of pyrroloquinoline quinone with atorvastatin augments mitochondrial biogenesis and attenuates low grade inflammation in obese rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Blood Glucose; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Liver; Male; Mitochondria, Liver; Obesity; Organelle Biogenesis; PQQ Cofactor; Rats, Sprague-Dawley | 2020 |
PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
Topics: Animals; Apoptosis; Atorvastatin; Calcium Signaling; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Mitochondria, Heart; Myocytes, Cardiac; Obesity; PCSK9 Inhibitors; Proprotein Convertase 9; Rats, Wistar; Recovery of Function; Serine Proteinase Inhibitors; Ventricular Function, Left | 2020 |
Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis.
Topics: Animals; Antifungal Agents; Atorvastatin; Azoles; Candida albicans; Candidiasis, Oral; Candidiasis, Vulvovaginal; Disease Models, Animal; Drug Repositioning; Drug Resistance, Fungal; Female; Humans; Mice; Microbial Sensitivity Tests; Rats; Treatment Outcome | 2021 |
Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study.
Topics: Animals; Atorvastatin; Chemical and Drug Induced Liver Injury; Cholesterol, Dietary; Cricetinae; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rosuvastatin Calcium | 2021 |
Atorvastatin prevents hearing impairment in the presence of hyperlipidemia.
Topics: Aged; Animals; Antioxidants; Apoptosis; Atorvastatin; Cochlea; Diet, High-Fat; Disease Models, Animal; Hearing Loss; Humans; Hyperlipidemias; Male; Mice; Mitochondria; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Signal Transduction | 2020 |
Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Rabbits; Time Factors | 2020 |
Protective effects of Naoxintong capsule alone and in combination with ticagrelor and atorvastatin in rats with Qi deficiency and blood stasis syndrome.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Male; Qi; Rats; Rats, Sprague-Dawley; Ticagrelor | 2020 |
Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cytokines; Disease Models, Animal; Female; Lipid Metabolism; Mice; Mice, Knockout; Renal Insufficiency, Chronic; Sirolimus | 2021 |
Therapeutic Effects of Iron Chelation in Atorvastatin-Induced Intracranial Hemorrhage of Zebrafish Larvae.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Brain; Deferasirox; Disease Models, Animal; Dose-Response Relationship, Drug; Intracranial Hemorrhages; Iron Chelating Agents; Larva; Time Factors; Zebrafish | 2020 |
Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibric Acids; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rats | 2021 |
Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering.
Topics: Animals; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Biomarkers; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diet, Fat-Restricted; Disease Models, Animal; Down-Regulation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice, Inbred C57BL; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Receptors, LDL | 2020 |
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypercholesterolemia; Hyperlipidemias; Inflammation; Male; Metabolic Syndrome; Oxidative Stress; Rats; Silymarin; Triglycerides | 2021 |
Inducibility, but not stability, of atrial fibrillation is increased by NOX2 overexpression in mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Disease Models, Animal; Enzyme Induction; Enzyme Inhibitors; Heart Atria; Heart Rate; Mice, Transgenic; Myocytes, Cardiac; NADPH Oxidase 2; Signal Transduction; Superoxides; Time Factors | 2021 |
Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide.
Topics: Acute Kidney Injury; Animals; Apoptosis; Atorvastatin; Contrast Media; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Disease Models, Animal; Hydrogen Sulfide; Inflammation; Kidney; Male; Oxidative Stress; Protective Agents; Rats; Rats, Sprague-Dawley; Sulfides; Up-Regulation | 2020 |
Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation.
Topics: Animals; Atorvastatin; Brain; Brain Edema; Brain Injuries; Case-Control Studies; Caspase 1; Cell Line; Cytokines; Disease Models, Animal; DNA-Binding Proteins; Encephalitis; Hemin; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1beta; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Subarachnoid Hemorrhage | 2021 |
Grape seed extract improved the fertility-enhancing effect of atorvastatin in high-fat diet-induced testicular injury in rats: involvement of antioxidant and anti-apoptotic effects.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apoptosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Grape Seed Extract; Hypercholesterolemia; Infertility, Male; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Testis | 2021 |
Influence of atorvastatin on metabolic pattern of rats with pulmonary hypertension.
Topics: Animals; Arterial Pressure; Atorvastatin; Disease Models, Animal; Fatty Acids; Glycolysis; Humans; Hypertension, Pulmonary; Lung; Male; Metabolomics; Monocrotaline; Oxidation-Reduction; Pulmonary Artery; Rats; Vascular Remodeling | 2021 |
Antiangiogenic and Proapoptotic Activities of Atorvastatin and Ganoderma lucidum in Tumor Mouse Model via VEGF and Caspase-3 Pathways.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Atorvastatin; Caspase 3; Disease Models, Animal; Drugs, Chinese Herbal; Female; Mice; Reishi; Vascular Endothelial Growth Factor A | 2021 |
Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.
Topics: Alanine Transaminase; Animals; Atorvastatin; Biomarkers; Collagen; Disease Models, Animal; Drug Synergism; Endothelial Cells; Endothelin-1; Enzyme Activation; Hemodynamics; Hepatic Stellate Cells; Insulin Resistance; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyridazines; Weight Gain | 2021 |
Atorvastatin Enhances Inhibitory Effects of Irradiation on Tumor Growth by Reducing MSH2 Expression Both in Prostate Cancer Cells and Xenograft Tumor Models.
Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Heterografts; Humans; Male; Mice; Mice, Nude; MutS Homolog 2 Protein; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2022 |
Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.
Topics: Animals; Atorvastatin; Bile Acids and Salts; Biomarkers; Diet, High-Fat; Disease Models, Animal; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mice; Models, Biological; Non-alcoholic Fatty Liver Disease; Triglycerides | 2021 |
Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Heart; Hypoxia; Male; Mice; Mice, Inbred C57BL; Myocardial Ischemia; NF-E2-Related Factor 2; Oxidative Stress; Sleep Apnea, Obstructive | 2021 |
Celecoxib exhibits therapeutic potential in experimental model of hyperlipidaemia.
Topics: Animals; Atorvastatin; Celecoxib; Cholesterol; Coconut Oil; Disease Models, Animal; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Rats, Sprague-Dawley; Triglycerides | 2021 |
Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm.
Topics: Angiotensin II; Animals; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Apoptosis; Atorvastatin; Calcium Chloride; Cell Line; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Random Allocation | 2017 |
Anti hyperlipidemic and hepatoprotective effects of native date fruit variety "Aseel" (Phoenix dactylifera).
Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cytoprotection; Diet, High-Fat; Dietary Sucrose; Disease Models, Animal; Fruit; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Phoeniceae; Phytotherapy; Plant Extracts; Plants, Medicinal; Rats; Time Factors | 2016 |
Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers.
Topics: Animals; Aorta; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiotonic Agents; Chromium; Combined Modality Therapy; Dietary Supplements; Disease Models, Animal; Food-Drug Interactions; Gene Expression Regulation; Heart Ventricles; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Octoxynol; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Serum Albumin, Human; Serum Amyloid P-Component | 2017 |
Atorvastatin as a promising anticryptococcal agent.
Topics: Animals; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Cryptococcosis; Cryptococcus gattii; Disease Models, Animal; Drug Repositioning; Drug Therapy, Combination; Fluconazole; Male; Mice, Inbred C57BL; Survival Analysis; Treatment Outcome | 2017 |
Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Topics: Animal Feed; Animals; Aortic Diseases; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, LDL; Time Factors | 2017 |
Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Animals; Atorvastatin; Bone Density; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Osteoporosis; Ovariectomy; Rats; Rats, Wistar | 2017 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Models, Animal; Gene Expression; Immunohistochemistry; Lipid Metabolism; Male; Metformin; Plaque, Atherosclerotic; Rabbits | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Models, Animal; Glioblastoma; Humans; Mice; Neoplasms, Experimental; ras Proteins; Signal Transduction; Temozolomide; Tumor Cells, Cultured | 2017 |
Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Blood Urea Nitrogen; Contrast Media; Creatinine; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Kidney Tubules; Male; Myeloid Differentiation Factor 88; NF-kappa B; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2017 |
(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease.
Topics: Animals; Atorvastatin; Catechin; Disease Models, Animal; Down-Regulation; Fibrillar Collagens; Gene Expression; Humans; Liver Cirrhosis; Male; Mice, Inbred C57BL; Multigene Family; Non-alcoholic Fatty Liver Disease | 2017 |
Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Injuries, Traumatic; Disease Models, Animal; Immunologic Factors; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL | 2017 |
Atorvastatin Protects Kidney from Remote Reperfusion Injury.
Topics: Animals; Aorta, Abdominal; Atorvastatin; Combined Modality Therapy; Cytoprotection; Disease Models, Animal; Ischemic Postconditioning; Kidney; Kidney Diseases; Male; Protective Agents; Rats, Wistar; Regional Blood Flow; Reperfusion Injury; Time Factors | 2018 |
Model design for screening effective Antihyperlipidemic drugs using zebrafish system.
Topics: Animals; Atorvastatin; Biomarkers; Cholesterol; Diet, High-Fat; Disease Models, Animal; Drug Discovery; Ezetimibe; Fenofibrate; High-Throughput Screening Assays; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Triglycerides; Zebrafish | 2017 |
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley | 2018 |
Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cerebral Cortex; Cognition Disorders; Convulsants; Disease Models, Animal; Epilepsy; Female; Gene Expression Regulation; Hippocampus; Humans; Interleukin-1beta; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Pilocarpine; Seizures; Status Epilepticus | 2018 |
Effects of atorvastatin on autophagy in skeletal muscles of diabetic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Autophagy; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Lipid Metabolism; Male; Microtubule-Associated Proteins; Muscle, Skeletal; Rats, Sprague-Dawley; Streptozocin | 2018 |
Radioprotective effect of atorvastatin against ionizing radiation-induced nephrotoxicity in mice.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 3; Creatinine; Disease Models, Animal; Fibrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Glomerulus; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Radiation Protection; Radiation-Protective Agents; Radiation, Ionizing; Urea; X-Rays | 2018 |
Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bacteria; Diet, High-Fat; Disease Models, Animal; DNA, Bacterial; DNA, Ribosomal; Gastrointestinal Microbiome; Hypercholesterolemia; Male; Phylogeny; Rats; RNA, Ribosomal, 16S; Sequence Analysis, DNA | 2018 |
Role of cortical microbleeds in cognitive impairment: In vivo behavioral and imaging characterization of a novel murine model.
Topics: Animals; Atorvastatin; Brain; Cerebral Hemorrhage; Cognitive Dysfunction; Collagenases; Disease Models, Animal; Male; Mice; Positron Emission Tomography Computed Tomography | 2019 |
Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Caco-2 Cells; Diet, High-Fat; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Emulsions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Absorption; Male; Nanoparticles; Phospholipids; Rats; Rats, Sprague-Dawley; Treatment Outcome; Water | 2018 |
In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Cholesterol; Cyclodextrins; Disease Models, Animal; Drug Carriers; Drug Liberation; Fatty Liver; Feasibility Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nanostructures; Rats; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; Triglycerides | 2018 |
Subtle improvement of seizure susceptibility by atorvastatin treatment during epileptogenesis.
Topics: Animals; Atorvastatin; Convulsants; Dentate Gyrus; Disease Models, Animal; Epilepsy; Female; Male; Mice; Mice, Inbred C57BL; Pilocarpine; Seizures; Status Epilepticus | 2018 |
Renal protection by atorvastatin in a murine model of sickle cell nephropathy.
Topics: Anemia, Sickle Cell; Animals; Atorvastatin; Disease Models, Animal; Female; Kidney; Kidney Diseases; Male; Mice; Mice, Mutant Strains; NADPH Oxidase 2; NADPH Oxidase 4 | 2018 |
The preventive effects of atorvastatin and N-acetyl cysteine in experimentally induced ischemia-reperfusion injury in rats.
Topics: Acetylcysteine; Animals; Atorvastatin; Catalase; Cecal Diseases; Cecum; Disease Models, Animal; Female; Free Radical Scavengers; Glutathione Peroxidase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Volvulus; Male; Malondialdehyde; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase | 2018 |
Atorvastatin dose-dependently promotes mouse lung repair after emphysema induced by elastase.
Topics: Animals; Atorvastatin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Leukocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Neutrophils; Oxidative Stress; Pancreatic Elastase; Pulmonary Emphysema; Swine; Time Factors | 2018 |
Atorvastatin Attenuates Metabolic Remodeling in Ischemic Myocardium through the Downregulation of UCP2 Expression.
Topics: Angiotensin II; Animals; Atorvastatin; Coronary Vessels; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Rats; Uncoupling Protein 2 | 2018 |
Atorvastatin ameliorates early brain injury through inhibition of apoptosis and ER stress in a rat model of subarachnoid hemorrhage.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Apoptosis; Apoptosis Regulatory Proteins; Aquaporin 4; Atorvastatin; Brain; Brain Injuries; Caspase 3; Disease Models, Animal; Drug Repositioning; Endoplasmic Reticulum Stress; Gene Expression Regulation; Heat-Shock Proteins; Male; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Subarachnoid Hemorrhage, Traumatic; Transcription Factor CHOP; Water | 2018 |
Evaluating intimal hyperplasia under clinical conditions.
Topics: Adventitia; Animals; Atorvastatin; Carotid Artery, Common; Constriction, Pathologic; Disease Models, Animal; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Jugular Veins; Swine; Tunica Intima; Vascular Surgical Procedures | 2018 |
A Single Dose of Atorvastatin Applied Acutely after Spinal Cord Injury Suppresses Inflammation, Apoptosis, and Promotes Axon Outgrowth, Which Might Be Essential for Favorable Functional Outcome.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Survival; Disease Models, Animal; Female; Interleukin-1beta; Macrophages; Neuronal Outgrowth; Rats; Rats, Wistar; Spinal Cord Injuries | 2018 |
The Ossabaw Pig Is a Suitable Translational Model to Evaluate Dietary Patterns and Coronary Artery Disease Risk.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Diet, Healthy; Diet, Western; Dietary Fats; Disease Models, Animal; Dyslipidemias; Energy Intake; Fatty Acids; Feeding Behavior; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Risk Factors; Swine; Triglycerides | 2018 |
Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Atorvastatin; Buthionine Sulfoximine; Ciprofloxacin; Creatine Kinase; Disease Models, Animal; Drug Interactions; Female; Glutathione Synthase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Rhabdomyolysis | 2018 |
Rapid inhibition of atherosclerotic plaque progression by sonodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Aortic Diseases; Apoptosis; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Peripheral Arterial Disease; Pilot Projects; Plaque, Atherosclerotic; Rabbits; Time Factors; Treatment Outcome; Ultrasonic Therapy | 2019 |
[Establishment of vulnerable plaque model by mast cell activation in adventitia and evaluation of effectiveness of intervention of Shenlian tablet].
Topics: Adventitia; Animals; Atorvastatin; C-Reactive Protein; Cell Degranulation; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Histamine; Interleukin-1beta; Lipoproteins, HDL; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice, Knockout, ApoE; NF-kappa B; Plaque, Atherosclerotic; Random Allocation; Rats; Tablets | 2016 |
[Protective effects of combined use of atorvastatin and low molecular weight heparin on the inflammatory reaction and pulmonary functions in rats with sepsis].
Topics: Animals; Atorvastatin; Cytokines; Disease Models, Animal; Heparin, Low-Molecular-Weight; HMGB1 Protein; Inflammation; Interleukin-1beta; Interleukin-6; Lung; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Tumor Necrosis Factor-alpha | 2016 |
Chronic atorvastatin and exercise can partially reverse established skeletal muscle microvasculopathy in metabolic syndrome.
Topics: Animals; Atorvastatin; Biomarkers; Disease Models, Animal; Epoprostenol; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Microcirculation; Microvessels; Models, Cardiovascular; Muscle, Skeletal; Nitric Oxide; Oxygen Consumption; Peripheral Vascular Diseases; Physical Conditioning, Animal; Physical Exertion; Rats, Zucker; Regional Blood Flow; Running; Thromboxane A2; Time Factors | 2018 |
Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in Watanabe heritable hyperlipidemic rabbit.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Disease Models, Animal; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mitochondria, Heart; Myocardium; Oxidative Stress; Oxygen Consumption; Rabbits; Reactive Oxygen Species; Time Factors | 2018 |
Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biological Availability; Delayed-Action Preparations; Diet, High-Fat; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Hyperlipidemias; Lipids; Lipoproteins; Liver; Nanoparticles; Rats; Rats, Wistar | 2018 |
Atorvastatin Pretreatment Attenuates Ischemic Brain Edema by Suppressing Aquaporin 4.
Topics: Animals; Aquaporin 4; Atorvastatin; Behavior, Animal; Body Water; Brain; Brain Edema; Disease Models, Animal; Down-Regulation; Infarction, Middle Cerebral Artery; Male; Motor Activity; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Apoptosis; Atorvastatin; Cell Line; Cell Survival; Disease Models, Animal; Hypertrophy, Left Ventricular; Male; MicroRNAs; Myocytes, Cardiac; Nerve Tissue Proteins; Rats, Sprague-Dawley; Signal Transduction; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats.
Topics: Animals; Atherosclerosis; Atorvastatin; China; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Inflammation; Interleukin-18; Interleukin-6; Lipoproteins, HDL; Lipoproteins, LDL; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes; Tumor Necrosis Factor-alpha | 2018 |
Assessment of the MRI and Behavioral Test Results in a Focal Cerebral Ischemia-Reperfusion Model in the Rat after Separate and Combined Use of Mouse-Derived Neural Progenitor Cells, Human-Derived Neural Progenitor Cells and Atorvastatin.
Topics: Animals; Atorvastatin; Behavior Rating Scale; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Mice; Neural Stem Cells; Rats; Recovery of Function; Reperfusion Injury; Stroke | 2018 |
Apelin‑13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high‑fat diet.
Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Heart Function Tests; Hemodynamics; Intercellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Metformin; Oxidation-Reduction; Protective Agents; Rats | 2018 |
Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis.
Topics: Actins; Animals; Atorvastatin; Azepines; Carbon Tetrachloride; Chitosan; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Synergism; HEK293 Cells; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Nuclear Proteins; Transcription Factors; Treatment Outcome; Triazoles; Vitamin A | 2019 |
Using zebrafish larval models to study brain injury, locomotor and neuroinflammatory outcomes following intracerebral haemorrhage.
Topics: Animals; Atorvastatin; Brain; Brain Injuries; Cerebral Hemorrhage; Disease Models, Animal; Immunity, Innate; Inflammation; Larva; Locomotion; Macrophage Activation; Mutation; Phagocytosis; Phenotype; Zebrafish | 2018 |
Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Restenosis; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium; Gene Expression Regulation; Humans; Inflammation; Interleukin-1; Interleukin-12; Interleukin-6; Interleukin-8; NF-kappa B; Rabbits; Tumor Necrosis Factor-alpha | 2018 |
Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways.
Topics: Animals; Apoptosis; Atorvastatin; Cardiotoxicity; Caspase 3; Disease Models, Animal; Doxorubicin; Fibrosis; Heart Failure; Heart Ventricles; HSP70 Heat-Shock Proteins; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Adiposity; Animals; Atorvastatin; Cachexia; Carcinoma, Lewis Lung; Disease Models, Animal; Gene Deletion; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Survival Analysis; Syndrome; Toll-Like Receptor 4; Tumor Cells, Cultured | 2018 |
Atorvastatin Prevents Myocardial Fibrosis in Spontaneous Hypertension via Interleukin-6 (IL-6)/Signal Transducer and Activator of Transcription 3 (STAT3)/Endothelin-1 (ET-1) Pathway.
Topics: Animals; Atorvastatin; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Endomyocardial Fibrosis; Endothelin-1; Fibrosis; Hypertension; Interleukin-6; Male; Myocardium; Phosphorylation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; STAT3 Transcription Factor | 2019 |
Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice.
Topics: Animals; Antidepressive Agents; Atorvastatin; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Lipopolysaccharides; Male; Mice; Neuroprotective Agents; Oxidative Stress; Prefrontal Cortex; Tumor Necrosis Factor-alpha | 2019 |
Atorvastatin Protects Against Cerebral Aneurysmal Degenerative Pathology by Promoting Endothelial Progenitor Cells (EPC) Mobilization and Attenuating Vascular Deterioration in a Rat Model.
Topics: Animals; Atorvastatin; Cell Movement; Disease Models, Animal; Endothelial Progenitor Cells; Hematopoietic Stem Cell Mobilization; Intracranial Aneurysm; Male; Protective Agents; Rats; Rats, Sprague-Dawley | 2019 |
Statins' Withdrawal Induces Atherosclerotic Plaque Destabilization in Animal Model-A "Rebound" Stimulation of Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Collagen; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Mice, Knockout, ApoE; Plaque, Atherosclerotic; Rupture, Spontaneous; Signal Transduction; Time Factors | 2019 |
Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Diclofenac; Disease Models, Animal; Drug Combinations; Drug Dosage Calculations; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Prednisolone; Rats; Treatment Outcome | 2020 |
Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19.
Topics: Angiogenic Proteins; Animals; Apoptosis; Atorvastatin; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Endothelial Cells; Exosomes; Female; Humans; Inflammation Mediators; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocytes, Cardiac; Neovascularization, Physiologic; Rats, Sprague-Dawley; Recovery of Function; RNA, Long Noncoding; Up-Regulation; Ventricular Function, Left | 2020 |
The effects of atorvastatin on the kidney injury in mice with pulmonary fibrosis.
Topics: Animals; Atorvastatin; Bleomycin; Cell Proliferation; Disease Models, Animal; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Signal Transduction | 2019 |
Statins exacerbate glucose intolerance and hyperglycemia in a high sucrose fed rodent model.
Topics: Animals; Atorvastatin; Diet; Disease Models, Animal; Fatty Acids; Feeding Behavior; Gene Expression Regulation; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Insulin; Muscles; Rats; Signal Transduction; Simvastatin; Sucrose | 2019 |
Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction.
Topics: Acute Disease; Animals; Atorvastatin; Disease Models, Animal; Humans; Male; Mesenchymal Stem Cells; Myocardial Infarction; Rats; Time Factors | 2019 |
Sphingolipidomics Investigation of the Temporal Dynamics after Ischemic Brain Injury.
Topics: Animals; Atorvastatin; Brain; Brain Injuries; Brain Ischemia; Ceramides; Chromatography, High Pressure Liquid; Disease Models, Animal; Humans; Infarction, Middle Cerebral Artery; Lipidomics; Lysophospholipids; Mice; Sphingolipids; Sphingosine; Stroke; Tandem Mass Spectrometry | 2019 |
Atorvastatin Attenuates Cold-Induced Hypertension by Preventing Gut Barrier Injury.
Topics: Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Aorta, Thoracic; Arterial Pressure; Atorvastatin; Cold Temperature; Colon; Cytokines; Disease Models, Animal; Hypertension; Hypothermia, Induced; Inflammation Mediators; Intestinal Mucosa; Nitric Oxide; Nitric Oxide Synthase Type III; Permeability; Phosphorylation; Rats, Sprague-Dawley; Signal Transduction; Tight Junctions | 2019 |
Atorvastatin Blocks Advanced Glycation End Products Induced Reduction in Macrophage Cholesterol Efflux Mediated With ATP-Binding Cassette Transporters G 1.
Topics: Animals; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol; Disease Models, Animal; Down-Regulation; Glycation End Products, Advanced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages, Peritoneal; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Receptor for Advanced Glycation End Products; THP-1 Cells | 2019 |
Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Heptanoic Acids; Hypoxia; Oxidative Stress; Pyrroles; Rats; Treatment Outcome | 2013 |
Altered microRNA expression in the ischemic-reperfusion spinal cord with atorvastatin therapy.
Topics: Animals; Atorvastatin; Disease Models, Animal; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MicroRNAs; Neuroprotective Agents; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Spinal Cord; Spinal Cord Ischemia | 2013 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Atorvastatin; Brain; Cognition Disorders; Cytokines; Disease Models, Animal; Food Preferences; Heptanoic Acids; Male; Maze Learning; Mood Disorders; Motor Activity; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Social Behavior; Sucrose; Sweetening Agents; Swimming; Tyrosine 3-Monooxygenase | 2013 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.
Topics: Animals; Antimalarials; Atorvastatin; Disease Models, Animal; Drug Synergism; Female; Heptanoic Acids; Kaplan-Meier Estimate; Malaria, Cerebral; Methylene Blue; Mice; Mice, Inbred C57BL; Parasitemia; Pyrroles | 2013 |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Mice, Transgenic; Osteoarthritis; Pyrroles | 2014 |
Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.
Topics: Animals; Antimalarials; Apoptosis; Artemether; Artemisinins; Atorvastatin; Blood-Brain Barrier; Caspases; Cell Count; Chemokine CXCL10; Disease Models, Animal; Drug Interactions; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; Heptanoic Acids; Humans; Leukocytes; Malaria, Cerebral; Membrane Proteins; Mice; Mice, Inbred C57BL; Models, Molecular; Neuroglia; Nucleic Acid Conformation; Pyrroles; Survival Analysis | 2013 |
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
Topics: Animals; Atorvastatin; Cerebral Cortex; Disease Models, Animal; Gene Expression; Heptanoic Acids; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase Type II; PPAR alpha; Pyrroles; Stroke; Vascular Cell Adhesion Molecule-1 | 2014 |
Focal histopathological progression of porcine experimental abdominal aortic aneurysm is mitigated by atorvastatin.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Disease Models, Animal; Disease Progression; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Elastase; Pyrroles; Sus scrofa; Time Factors; Ultrasonography | 2013 |
Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Gene Expression; Heptanoic Acids; Histocytochemistry; Male; Pyrroles; Rabbits; Random Allocation; Toll-Like Receptor 4; Transcription Factor RelA | 2013 |
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
Topics: Animals; Apoptosis; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Swine; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6⁻/⁻).
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Calcinosis; Calcium; Connective Tissue; Dermis; Disease Models, Animal; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mice; Mice, Knockout; Pseudoxanthoma Elasticum; Pyrroles | 2013 |
MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Atorvastatin; Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Down-Regulation; Heptanoic Acids; Male; Mice; MicroRNAs; Myocardium; Myocytes, Cardiac; Myosin Heavy Chains; Natriuretic Peptide, Brain; Oligonucleotides, Antisense; Phosphoric Monoester Hydrolases; PTEN Phosphohydrolase; Pyrroles; Rats | 2013 |
Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats.
Topics: Analgesia; Animals; Anti-Inflammatory Agents; Atorvastatin; Constriction; Dinoprostone; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Male; Matrix Metalloproteinase 2; Nerve Growth Factor; Neuralgia; Pain Measurement; Pyrroles; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Tumor Necrosis Factor-alpha | 2013 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Matrix Metalloproteinases; Mice; Mice, Knockout; Pyrroles; rho-Associated Kinases | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; Artemisinins; Atorvastatin; Biomarkers; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Inflammation; Malaria, Cerebral; Mice; Mice, Inbred C57BL; Pyrroles; Survival Analysis; Treatment Outcome | 2013 |
Atorvastatin improves microenvironment to enhance the beneficial effects of BMSCs therapy in a rabbit model of acute myocardial infarction.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocytes, Cardiac; Pyrroles; Rabbits | 2013 |
Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis.
Topics: Animals; Atorvastatin; Brain; Cytokines; Disease Models, Animal; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes, Regulatory; Tretinoin; Weight Loss | 2014 |
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.
Topics: Allografts; Animals; Atorvastatin; Biopsy; Cohort Studies; Dasatinib; Databases as Topic; Disease Models, Animal; Drug Approval; Electronic Health Records; Gene Expression Regulation; Gene Regulatory Networks; Graft Rejection; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Kidney; Kidney Transplantation; Meta-Analysis as Topic; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Organ Specificity; Pyrimidines; Pyrroles; Reproducibility of Results; Retrospective Studies; Thiazoles; Transplantation; United States; United States Food and Drug Administration | 2013 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Topics: Animals; Apolipoproteins E; Atorvastatin; CD36 Antigens; Cholesterol; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Feedback, Physiological; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; RNA Interference; Scavenger Receptors, Class A; Stress, Physiological; Time Factors; Transfection | 2014 |
The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline.
Topics: Administration, Oral; Animals; Atorvastatin; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory; Mice; Mice, Inbred C57BL; Nephrectomy; Postoperative Complications; Pyrroles; Recovery of Function; Treatment Outcome | 2014 |
10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits.
Topics: Animals; Atorvastatin; C-Reactive Protein; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Models, Animal; Dyslipidemias; Guaiacol; Heptanoic Acids; Inflammation; Male; Mass Spectrometry; Oxygen; Pyrroles; Rabbits; Risk Factors | 2013 |
The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cytokines; Disease Models, Animal; Drug Synergism; Feces; Heptanoic Acids; Male; Mice; Mice, Knockout; Molecular Mimicry; Plaque, Atherosclerotic; Pyrroles; Thyroid Hormones | 2013 |
Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension.
Topics: Animals; Aorta; Atorvastatin; Blood Pressure; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hypertension, Renovascular; Male; Nitric Oxide; Piperazines; Purines; Pyrroles; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2013 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Nitric Oxide Synthase Type III; Pyrroles; Rats, Inbred Dahl; Scavenger Receptors, Class E; Sodium Chloride, Dietary; Superoxides; Time Factors; Vasodilation | 2014 |
Atorvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in rats.
Topics: Acute Kidney Injury; Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Glomerular Filtration Rate; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Treatment Outcome | 2014 |
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
Topics: Adenylyl Cyclases; Animals; Atorvastatin; Cell Differentiation; Cell Proliferation; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; Rats; STAT6 Transcription Factor; T-Lymphocytes, Regulatory; Th2 Cells | 2014 |
Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Occlusion; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Inflammation; Interferon-gamma; Interleukin-6; Ligation; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; No-Reflow Phenomenon; Pyrroles; Rabbits; Random Allocation | 2014 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Role of calcifying nanoparticle in the development of hyperplasia and vascular calcification in an animal model.
Topics: Angioplasty, Balloon; Animals; Atorvastatin; Calcifying Nanoparticles; Carotid Arteries; Carotid Artery Injuries; Carotid Intima-Media Thickness; Cholesterol; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Male; Muscle, Smooth, Vascular; Neointima; Pyrroles; Rabbits; Time Factors; Triglycerides; Vascular Calcification | 2014 |
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure, Diastolic; Heptanoic Acids; HSP47 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium; Pyrroles; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Ventricular Function, Left | 2014 |
Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Blood Cell Count; Brain; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hematoma, Subdural; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Inflammation; Lipids; Magnetic Resonance Imaging; Male; Neurologic Examination; Pyrroles; Rats; Rats, Wistar; Time Factors | 2014 |
Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.
Topics: Abietanes; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Salvia miltiorrhiza; Treatment Outcome | 2014 |
Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model.
Topics: Analgesics; Animals; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometriosis; Endometrium; Female; Heptanoic Acids; Humans; Leuprolide; Nociception; Nociceptive Pain; Pyrroles; Rats; Rats, Wistar; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
GluN2B N-methyl-D-aspartic acid receptor subunit mediates atorvastatin-Induced neuroprotection after focal cerebral ischemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Embryo, Mammalian; Heptanoic Acids; Male; Maze Learning; Nerve Tissue Proteins; Nervous System Diseases; Piperidines; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Somatosensory Cortex; Time Factors | 2014 |
Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E-deficient mice.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-3 Receptor Antagonists; Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heptanoic Acids; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha; PPAR gamma; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta-3; RNA, Messenger | 2014 |
Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images.
Topics: Algorithms; Animals; Atorvastatin; Blood Flow Velocity; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Image Processing, Computer-Assisted; Male; Pyrroles; Rabbits; Ultrasonography, Doppler; Vasodilator Agents | 2014 |
HspB8 expression in brain tissue after cerebral ischemic reperfusion and atorvastatin intervention in Sprague-Dawley rats.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Heat-Shock Proteins; Heptanoic Acids; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; Neurons; Neuroprotective Agents; Pyrroles; Random Allocation; Rats, Sprague-Dawley; Reperfusion Injury; Severity of Illness Index; Tetrazolium Salts | 2015 |
Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy.
Topics: Angiotensin II; Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Heptanoic Acids; Humans; Kidney; Kidney Diseases; Mice; Monomeric GTP-Binding Proteins; Pyrroles; Receptor, Angiotensin, Type 1; Signal Transduction; Ureteral Obstruction | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Artery Injuries; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immunosorbent Assay; fas Receptor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; In Situ Nick-End Labeling; Male; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Neointima; Pyrroles; Rats; Survivin | 2014 |
Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Plaque, Atherosclerotic; Porphyromonas gingivalis; Pyrroles; Rabbits; Vascular Cell Adhesion Molecule-1 | 2014 |
Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
Topics: Animals; Atorvastatin; Base Sequence; Blood Vessels; Cholesterol, LDL; Disease Models, Animal; Embryo, Nonmammalian; Gene Expression Regulation; Gene Knockdown Techniques; Hepatomegaly; Heptanoic Acids; Hypercholesterolemia; Liver; Molecular Sequence Data; Morpholinos; Oxidation-Reduction; Pyrroles; Receptors, LDL; Veins; Zebrafish | 2014 |
Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome.
Topics: Animals; Atorvastatin; Autophagy; Biomarkers; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Pyrroles; Signal Transduction; Swine | 2014 |
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; gamma-Glutamyltransferase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Evaluation of the Anti-inflammatory Activity of Atorvastatin and its Effect on Alveolar Diameter in a Model of Elastase-induced Emphysema in Rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Disease Models, Animal; Inflammation; Leukocytes; Male; Nitric Oxide; Pancreatic Elastase; Pulmonary Alveoli; Pulmonary Emphysema; Rats; Rats, Wistar | 2015 |
Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Coagulation; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Dyslipidemias; Endothelin-1; Endothelium, Vascular; Guaiacol; Nitric Oxide; Plasminogen Activator Inhibitor 1; Rabbits; Treatment Outcome | 2015 |
HMG-CoA reductase inhibitor rosuvastatin improves abnormal brain electrical activity via mechanisms involving eNOS.
Topics: Animals; Anticonvulsants; Atorvastatin; bcl-2-Associated X Protein; Blood-Brain Barrier; Brain; Capillary Permeability; Caspase 3; Disease Models, Animal; Epilepsy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase Type III; Penicillin G; Random Allocation; Rats, Sprague-Dawley; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Tumor Suppressor Protein p53 | 2015 |
Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications.
Topics: Angiotensin-Converting Enzyme 2; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Epigenesis, Genetic; Heptanoic Acids; Histones; Male; Peptidyl-Dipeptidase A; Pyrroles; Rabbits; Tissue Distribution; Up-Regulation | 2015 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Role of inflammation in the initiation and maintenance of atrial fibrillation and the protective effect of atorvastatin in a goat model of aseptic pericarditis.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Cardiac Surgical Procedures; Cytokines; Disease Models, Animal; Goats; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Pericarditis; Pyrroles | 2015 |
Protection effect of atorvastatin in cerebral ischemia-reperfusion injury rats by blocking the mitochondrial permeability transition pore.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Brain Ischemia; Cytochromes c; Disease Models, Animal; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pyrroles; Rats, Sprague-Dawley; Reperfusion Injury | 2014 |
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Topics: Animals; Atorvastatin; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Fatty Acids, Omega-3; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sucrose | 2015 |
Anti-inflammatory and chondroprotective effects of atorvastatin in a cartilage explant model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cartilage, Articular; Cell Survival; Disease Models, Animal; Glycosaminoglycans; In Vitro Techniques; Interleukin-1beta; Male; Matrix Metalloproteinase 13; Nitric Oxide; Osteoarthritis; Protective Agents; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha | 2015 |
Pre-treatment of a single high-dose of atorvastatin provided cardioprotection in different ischaemia/reperfusion models via activating mitochondrial KATP channel.
Topics: Animals; Atorvastatin; Calcium; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Glucose; Heart Ventricles; Hemodynamics; L-Lactate Dehydrogenase; Male; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen; Potassium Channels; Rats; Reactive Oxygen Species; Risk | 2015 |
Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion injury.
Topics: Animals; Atorvastatin; Biopsy; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Malondialdehyde; Neuroprotective Agents; Nitric Oxide; Paraplegia; Pyrroles; Rabbits; Random Allocation; Reperfusion Injury; Reproducibility of Results; Spinal Cord Ischemia; Superoxide Dismutase; Time Factors | 2015 |
The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats.
Topics: Animal Feed; Animals; Atorvastatin; Bone Density; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; X-Ray Microtomography | 2015 |
Combined treatment with atorvastatin and imipenem improves survival and vascular functions in mouse model of sepsis.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipenem; Male; Mice; Organ Culture Techniques; Sepsis; Survival Rate | 2015 |
Atorvastatin prevents neuroinflammation in chronic constriction injury rats through nuclear NFκB downregulation in the dorsal root ganglion and spinal cord.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Nucleus; Chronic Disease; Constriction, Pathologic; Disease Models, Animal; Down-Regulation; Ganglia, Spinal; Hyperalgesia; Male; Microglia; Neuralgia; Neuroimmunomodulation; NF-kappa B; Rats, Sprague-Dawley; Spinal Cord; Time Factors; Treatment Outcome | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Paradoxical effects of atorvastatin on renal tubular cells: an experimental investigation.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Dose-Response Relationship, Drug; Gentamicins; Kidney; Kidney Tubules; Male; Rats; Rats, Wistar; Time Factors; Treatment Outcome | 2015 |
Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; CD40 Ligand; Cholesterol; Contrast Media; Dextrans; Diet, High-Fat; Disease Models, Animal; Gene Expression; Hypercholesterolemia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Matrix Metalloproteinase 9; Plaque, Atherosclerotic; Rabbits; Succimer; Transgenes; Tumor Suppressor Protein p53 | 2015 |
The hypolipidemic effect of artesunate and ursolic acid in rats.
Topics: Animals; Artemisinins; Artesunate; Atorvastatin; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Rats; Triglycerides; Triterpenes; Ursolic Acid | 2015 |
Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Blood Glucose; Caspase 3; Diabetic Cardiomyopathies; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Malondialdehyde; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Oxidative Stress; Rats | 2015 |
Acute perioperative-stress-induced increase of atherosclerotic plaque volume and vulnerability to rupture in apolipoprotein-E-deficient mice is amenable to statin treatment and IL-6 inhibition.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Laparotomy; Lipoproteins; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Perioperative Period; Plaque, Atherosclerotic; Rupture; Serum Amyloid A Protein; Signal Transduction | 2015 |
Efficacy of atorvastatin on hippocampal neuronal damage caused by chronic intermittent hypoxia: Involving TLR4 and its downstream signaling pathway.
Topics: Animals; Atorvastatin; Chronic Disease; Disease Models, Animal; Hippocampus; Hypoxia; Interleukin-1beta; Male; Malondialdehyde; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Neurons; Neuroprotective Agents; Random Allocation; Signal Transduction; Sleep Apnea, Obstructive; Superoxide Dismutase; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cell Line, Tumor; Citrulline; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Sucrose; Disease Models, Animal; Drug Therapy, Combination; Glucose; Homeostasis; Humans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; Sterol Regulatory Element Binding Protein 1 | 2015 |
Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin.
Topics: Achilles Tendon; Aged, 80 and over; Animals; Atorvastatin; Biomechanical Phenomena; Bone Density; Calcinosis; Disease Models, Animal; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rats, Wistar; Risk Factors; Rosuvastatin Calcium; Rupture, Spontaneous; Simvastatin; Tendinopathy | 2017 |
Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis.
Topics: Animals; Atorvastatin; B7-1 Antigen; B7-2 Antigen; Dendritic Cells; Disease Models, Animal; Female; Flow Cytometry; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Humoral; Interleukins; Myasthenia Gravis, Autoimmune, Experimental; Rats; Rats, Inbred Lew; Receptors, Cholinergic; Time Factors | 2015 |
Effects of atorvastatin on PDCD4/NF-κB/TNF-α signaling pathway during coronary microembolization of miniature pigs.
Topics: Animals; Atorvastatin; Blotting, Western; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Embolism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; NF-kappa B; Percutaneous Coronary Intervention; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Swine; Swine, Miniature; Tumor Necrosis Factor-alpha | 2015 |
Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension.
Topics: Animals; Aorta; Atorvastatin; Cardiovascular Agents; Collagen; Disease Models, Animal; Drug Combinations; Drug Synergism; Endothelium, Vascular; Gene Expression Regulation; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Myocytes, Smooth Muscle; Oxidative Stress; Platelet-Derived Growth Factor; Rats; Rats, Wistar; Reactive Oxygen Species; Signal Transduction; Sildenafil Citrate; Transforming Growth Factor beta; Vascular Remodeling | 2015 |
Atorvastatin protects myocardium against ischemia-reperfusion arrhythmia by increasing Connexin 43 expression: A rat model.
Topics: Animals; Arrhythmias, Cardiac; Atorvastatin; Connexin 43; Creatine Kinase, MB Form; Cytoprotection; Disease Models, Animal; Heart Rate; L-Lactate Dehydrogenase; Male; Myocardium; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Reperfusion Injury; Signal Transduction; Up-Regulation | 2015 |
Robust and enduring atorvastatin-mediated memory recovery following the 4-vessel occlusion/internal carotid artery model of chronic cerebral hypoperfusion in middle-aged rats.
Topics: Aging; Amnesia, Retrograde; Animals; Atorvastatin; Brain; Cerebrovascular Disorders; Chronic Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Maze Learning; Memory; Nootropic Agents; Pyramidal Cells; Rats, Wistar; Treatment Outcome | 2016 |
Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.
Topics: Actin Depolymerizing Factors; Amides; Animals; Atorvastatin; Binding Sites; Cerebral Hemorrhage; Databases, Chemical; Databases, Protein; Disease Models, Animal; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrroles; rho-Associated Kinases; Signal Transduction; Structure-Activity Relationship; Zebrafish | 2015 |
Resolvin Infectious Inflammation by Targeting the Host Response.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Docosahexaenoic Acids; Endothelial Cells; Escherichia coli Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Neutrophils; Phagocytosis; Sepsis | 2015 |
Atorvastatin Inhibits Myocardial Apoptosis in a Swine Model of Coronary Microembolization by Regulating PTEN/PI3K/Akt Signaling Pathway.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Down-Regulation; Echocardiography; Embolism; Myocardial Infarction; Myocardium; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Small Interfering; Signal Transduction; Swine; Troponin I | 2016 |
Statin Therapy and the Development of Cerebral Amyloid Angiopathy--A Rodent in Vivo Approach.
Topics: Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Atorvastatin; Cerebral Amyloid Angiopathy; Cerebral Hemorrhage; Disease Models, Animal; Gene Expression; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic | 2016 |
Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
Topics: Animal Feed; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Fibrillin-1; Hypercholesterolemia; Kaplan-Meier Estimate; Mice, Knockout; Plaque, Atherosclerotic; Survival Analysis | 2016 |
Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atorvastatin; Cytokines; Disease Models, Animal; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Maze Learning; Mice, Inbred C57BL | 2016 |
Simvastatin and atorvastatin facilitates amyloid β-protein degradation in extracellular spaces by increasing neprilysin secretion from astrocytes through activation of MAPK/Erk1/2 pathways.
Topics: Amyloid beta-Peptides; Animals; Astrocytes; Atorvastatin; Brain; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Extracellular Space; MAP Kinase Signaling System; Neprilysin; Rats, Sprague-Dawley; Simvastatin | 2016 |
A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig.
Topics: Animals; Animals, Genetically Modified; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Femoral Artery; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Receptors, LDL; Swine; Swine, Miniature; Translational Research, Biomedical | 2016 |
Varicose Remodeling of Veins Is Suppressed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors.
Topics: Animals; Atorvastatin; Case-Control Studies; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rosuvastatin Calcium; Signal Transduction; Time Factors; Transcription Factor AP-1; Varicose Veins; Vascular Remodeling; Veins | 2016 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cross-Sectional Studies; Disease Models, Animal; Gene Expression Profiling; Hydroxyproline; Hypertension; Immunohistochemistry; Male; Myocardium; NF-kappa B; Osteoprotegerin; RANK Ligand; Rats, Inbred SHR; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Ventricular Function, Left | 2016 |
Atorvastatin enhances angiogenesis to reduce subdural hematoma in a rat model.
Topics: AC133 Antigen; Analysis of Variance; Angiopoietin-1; Animals; Anticholesteremic Agents; Antigens, CD34; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Progenitor Cells; Gene Expression Regulation; Hematoma, Subdural; Magnetic Resonance Imaging; Male; Matrix Metalloproteinase 9; Microscopy, Electron, Transmission; Neovascularization, Physiologic; Rats; Rats, Wistar; RNA, Messenger; Time Factors; Vascular Endothelial Growth Factor A | 2016 |
Profiling analysis of amino acids from hyperlipidaemic rats treated with Gynostemma pentaphyllum and atorvastatin.
Topics: Amino Acids; Animals; Atorvastatin; Biomarkers; Chromatography, Liquid; Diet, High-Fat; Discriminant Analysis; Disease Models, Animal; Gynostemma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Least-Squares Analysis; Lipids; Liver; Male; Metabolomics; Multivariate Analysis; Phytotherapy; Plant Extracts; Plants, Medicinal; Principal Component Analysis; Rats; Solid Phase Extraction | 2016 |
The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Atorvastatin; Cardiovascular System; Carrier Proteins; CD40 Antigens; Coronary Circulation; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isolated Heart Preparation; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Time Factors; Vasodilation | 2016 |
Effects of atorvastatin and artichoke leaf tincture on oxidative stress in hypercholesterolemic rats.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cynara scolymus; Disease Models, Animal; Drug Monitoring; Drug Synergism; Herb-Drug Interactions; Hypercholesterolemia; Oxidative Stress; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Treatment Outcome | 2016 |
Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arginase; Atorvastatin; Cells, Cultured; Disease Models, Animal; GAP-43 Protein; Heart; Interleukin-1beta; Macrophage Activation; Macrophages, Peritoneal; Male; Myocardial Infarction; Myocardium; Nerve Growth Factor; Nitric Oxide Synthase Type II; Phenotype; Rats, Wistar; Sympathetic Nervous System; Tachycardia, Ventricular; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase; Ventricular Fibrillation | 2016 |
A non-hypocholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits.
Topics: Aging; Animals; Aorta; Arteries; Atherosclerosis; Atorvastatin; Blood Pressure; Collagen; Disease Models, Animal; Elastic Modulus; Elastin; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pulse Wave Analysis; Rabbits; Stress, Mechanical; Tensile Strength | 2016 |
Atorvastatin Combined Nitroglycerin Therapy Confer Additive Effects on Rabbits with Dyslipidemia.
Topics: Animals; Atorvastatin; Disease Models, Animal; Drug Therapy, Combination; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Nitroglycerin; Rabbits; rho-Associated Kinases; Vasodilator Agents | 2016 |
Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Atrial Function, Right; Atrial Remodeling; Blotting, Western; Cardiac Pacing, Artificial; Disease Models, Animal; DNA; Echocardiography; Electrocardiography; Heart Atria; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Peroxidase; Rabbits; Real-Time Polymerase Chain Reaction | 2016 |
Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Creatine Kinase; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lactic Acid; Male; Microscopy, Electron, Transmission; Mitochondria, Muscle; Motor Activity; Muscle, Skeletal; Muscular Diseases; Myoglobin; Pyruvic Acid; Rats; Rats, Sprague-Dawley; Ubiquinone | 2016 |
Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice.
Topics: Animals; Arginine; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Morphine; Narcotics; NG-Nitroarginine Methyl Ester; Nitric Oxide; Opioid-Related Disorders; Pain Measurement; Pain Threshold; Signal Transduction | 2016 |
Antagonistic effect of atorvastatin on high fat diet induced survival during acute Chagas disease.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chagas Cardiomyopathy; Diet, High-Fat; Disease Models, Animal; Male; Mice, Inbred C3H; Survival Analysis; Treatment Outcome | 2016 |
The role of atorvastatin on the restenosis process post-PTA in a diabetic rabbit model.
Topics: Angioplasty, Balloon; Animals; Atherosclerosis; Atorvastatin; Cell Movement; Cell Proliferation; Constriction, Pathologic; Diabetes Mellitus, Experimental; Disease Models, Animal; Iliac Artery; Male; Myocytes, Smooth Muscle; Neointima; Rabbits; Recurrence; Time Factors; Vascular Patency; Vascular System Injuries | 2016 |
Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Atorvastatin; Depression; Disease Models, Animal; Enzyme Inhibitors; Exploratory Behavior; Glycogen Synthase Kinase 3 beta; Hindlimb Suspension; Immunosuppressive Agents; Male; Mice; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2016 |
Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Atorvastatin; Biomarkers; C-Reactive Protein; Cytokines; Disease Models, Animal; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning; Male; Middle Aged; Myocardial Ischemia; Myocardial Reperfusion Injury; Nitric Oxide; Prospective Studies; Rabbits; Treatment Outcome; Young Adult | 2016 |
Atorvastatin Modulates Regulatory T Cells and Attenuates Cerebral Damage in a Model of Transient Middle Cerebral Artery Occlusion in Rats.
Topics: Animals; Atorvastatin; Brain; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Rats; Rats, Wistar; T-Lymphocytes, Regulatory | 2017 |
Involvement of peroxisome proliferator activated receptor-γ in the anti-inflammatory effects of atorvastatin in oxygen-glucose deprivation/reperfusion-stimulated RAW264.7 murine macrophages.
Topics: Animals; Atorvastatin; Disease Models, Animal; Gene Expression Regulation; Gene Knockdown Techniques; Glucose; Humans; Inflammation; Interferon-gamma; Lectins, C-Type; Mannose Receptor; Mannose-Binding Lectins; Mice; Nitric Oxide Synthase Type II; Oxygen; PPAR gamma; RAW 264.7 Cells; Receptors, Cell Surface; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2016 |
Atorvastatin alleviates cardiomyocyte apoptosis by suppressing TRB3 induced by acute myocardial infarction and hypoxia.
Topics: Animals; Apoptosis; Atorvastatin; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Myocardial Infarction; Myocytes, Cardiac; Protein Serine-Threonine Kinases; Rats; Rats, Wistar | 2017 |
A comparative study of the hypolipidaemic effects of a new polysaccharide, mannan Candida albicans serotype A, and atorvastatin in mice with poloxamer 407-induced hyperlipidaemia.
Topics: Animals; Atorvastatin; Biomarkers; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; Hexosaminidases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Droplets; Lipids; Liver; Macrophages, Peritoneal; Male; Mannans; Mice, Inbred CBA; Microscopy, Electron; Nitric Oxide; Poloxamer | 2016 |
Atorvastatin Improves Ventricular Remodeling after Myocardial Infarction by Interfering with Collagen Metabolism.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Catheter Ablation; Collagen; Disease Models, Animal; Fibrosis; Gene Expression; Heart Ventricles; Hemodynamics; Interleukin-1; Male; Matrix Metalloproteinase 1; Myocardial Infarction; Myocardium; NF-kappa B p50 Subunit; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1; Ventricular Remodeling | 2016 |
Atorvastatin alleviates renal ischemia-reperfusion injury in rats by promoting M1-M2 transition.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atorvastatin; Creatinine; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Interferon-gamma; Kidney; Macrophages; Male; Microscopy, Fluorescence; Mitosis; PPAR gamma; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Tumor Necrosis Factor-alpha; Up-Regulation | 2017 |
Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice.
Topics: Animals; Antioxidants; Astrocytes; Atorvastatin; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Tolerance; Male; Mice; Microglia; Morphine; Morphine Dependence; Naloxone; Narcotics; Nociception; Random Allocation; Substance Withdrawal Syndrome | 2017 |
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Atorvastatin; Cell Proliferation; Cholesterol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pyrroles; T-Lymphocytes; Treatment Outcome | 2008 |
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles | 2008 |
Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death.
Topics: Animals; Atorvastatin; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Ectodysplasins; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Inflammation; Interleukin-1beta; Kainic Acid; Male; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Tumor Necrosis Factor-alpha | 2008 |
Atorvastatin enhances hypothermia-induced neuroprotection after stroke.
Topics: Animals; Atorvastatin; Brain Infarction; CD11b Antigen; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnetic Resonance Imaging; Male; Neurologic Examination; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stroke | 2008 |
Atorvastatin efficiency after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Brain; Brain Edema; Brain Injuries; Cerebrovascular Circulation; Craniotomy; Disease Models, Animal; Heptanoic Acids; Lipid Peroxidation; Male; Microcirculation; Microscopy, Electron, Transmission; Neuroprotective Agents; Organ Size; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley | 2009 |
Atorvastatin inhibits renal crystal retention in a rat stone forming model.
Topics: Animals; Apoptosis; Atorvastatin; Biopsy, Needle; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Kidney Calculi; Kidney Tubules; Male; Oxalates; Oxidative Stress; Probability; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Statistics, Nonparametric; Superoxide Dismutase; Urinalysis | 2008 |
Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Atorvastatin; Carbon Tetrachloride; Cell Proliferation; Cells, Cultured; Chemical and Drug Induced Liver Injury; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; Hepatic Stellate Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Infusion Pumps, Implantable; Intercellular Adhesion Molecule-1; Interleukin-6; Liver; Male; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Transforming Growth Factor beta1 | 2009 |
Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Disease Models, Animal; Electric Stimulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Penile Erection; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Purines; Pyrroles; Rabbits; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfones | 2009 |
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner.
Topics: Animals; Atorvastatin; Cholesterol; Disease Models, Animal; Endothelium, Vascular; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Oxidative Stress; Pregnancy; Prenatal Exposure Delayed Effects; Protein-Energy Malnutrition; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Vasculitis; Vasoconstriction; Weight Gain | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Topics: Animals; Aorta; Arginine; Atherosclerosis; Atorvastatin; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Heme Oxygenase-1; Hemin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Metalloporphyrins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Protoporphyrins; Pyrroles; Rabbits; Simvastatin; Time Factors | 2009 |
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Mice; Models, Chemical; Neoplasms, Experimental; Pyrroles; Reactive Oxygen Species | 2008 |
Up-regulating PPAR-γ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Down-Regulation; Fibrinolytic Agents; Heptanoic Acids; Male; Nitric Oxide; Plasminogen Activator Inhibitor 1; PPAR gamma; Pyrroles; Rabbits; Up-Regulation | 2010 |
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Liver; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Rabbits; Sesquiterpenes; Time Factors | 2008 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids.
Topics: Analysis of Variance; Animals; Atorvastatin; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Male; Malondialdehyde; Mesenteric Arteries; Probability; Prostaglandins; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sensitivity and Specificity; Vasodilation | 2009 |
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
Topics: Animals; Atorvastatin; Body Weight; Cardiac Volume; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2010 |
Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. fruit in hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Cucurbitaceae; Dietary Fats; Disease Models, Animal; Feces; Fruit; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; Phytotherapy; Plant Extracts; Pyrroles; Rats; Rats, Wistar; Triglycerides; Weight Gain | 2009 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake.
Topics: Analysis of Variance; Animals; Atorvastatin; Cell Death; Complex Mixtures; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mice; Oncogene Protein v-akt; Phosphorylation; Pyrroles; Quinolinic Acid; Seizures; Tetrazolium Salts; Thiazoles; Tritium | 2009 |
Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Dietary Fats; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Insulin; Lipids; Male; Pyrroles; Rabbits; Vasculitis | 2011 |
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Atorvastatin; Cholesterol; Cystadenoma; Disease Models, Animal; Female; Hemangioma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Survival Rate; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2009 |
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Heptanoic Acids; Immunohistochemistry; Intracranial Embolism; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Stroke; Time Factors; Tissue Plasminogen Activator | 2009 |
Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Brain; Brain Infarction; Bromodeoxyuridine; Cerebral Hemorrhage; Cytoprotection; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microtubule-Associated Proteins; Nerve Degeneration; Neurogenesis; Neuronal Plasticity; Neuropeptides; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Regeneration; Simvastatin; Treatment Outcome | 2009 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine.
Topics: Analysis of Variance; Animals; Atorvastatin; Blotting, Western; Cell Nucleus; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Migraine Disorders; Neoplasm Proteins; Neurons; NF-kappa B; Nitroglycerin; Nucleocytoplasmic Transport Proteins; Pyrroles; Rats; Rats, Sprague-Dawley; Trigeminal Caudal Nucleus | 2009 |
Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis.
Topics: Acetylcholine; Animals; Aorta; Atorvastatin; Biological Factors; Blood Cell Count; Blood Pressure; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypotension; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Nitroprusside; Phenylephrine; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Sepsis; Vasodilation | 2009 |
FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol, Dietary; Diagnosis, Differential; Disease Models, Animal; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiopharmaceuticals | 2010 |
The functional changes of the perivascular adipose tissue in spontaneously hypertensive rats and the effects of atorvastatin therapy.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Connective Tissue; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasoconstriction; Vasodilation | 2009 |
Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; Pyrroles; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Binding, Competitive; Cells, Cultured; Contrast Media; Disease Models, Animal; Endothelium, Vascular; Feasibility Studies; Fluorodeoxyglucose F18; Graft Rejection; Half-Life; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Iopamidol; Ligands; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Peptides; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; RNA, Messenger; Tissue Distribution; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2009 |
Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways.
Topics: Analysis of Variance; Animals; Atorvastatin; Chi-Square Distribution; Disease Models, Animal; Free Radical Scavengers; Gentamicins; Heptanoic Acids; Immunohistochemistry; Kidney Function Tests; Kidney Tubular Necrosis, Acute; Male; MAP Kinase Signaling System; NF-kappa B; Nitric Oxide; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Probability; Pyrroles; Random Allocation; Rats; Rats, Wistar | 2009 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; Carotid Stenosis; Clopidogrel; Disease Models, Animal; Ethanolamines; Graft Occlusion, Vascular; Heptanoic Acids; Hyperplasia; Jugular Veins; Male; Nebivolol; Pyrroles; Rabbits; Ticlopidine; Tunica Intima; Vascular Surgical Procedures | 2009 |
Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury.
Topics: Analysis of Variance; Animals; Atorvastatin; Benzenesulfonates; Dietary Sucrose; Disease Models, Animal; Drug Administration Routes; Ectodysplasins; Exploratory Behavior; Food, Formulated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Motor Activity; Nervous System Diseases; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley; Sacrococcygeal Region; Simvastatin; Spinal Cord Injuries | 2010 |
Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
Topics: Animals; Atorvastatin; Chickens; Cholesterol; Disease Models, Animal; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2010 |
Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP.
Topics: Animals; Atorvastatin; Baroreflex; Blood Pressure; Disease Models, Animal; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medulla Oblongata; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2009 |
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate | 2010 |
Atorvastatin causes regression of endometriotic implants in a rat model.
Topics: Animals; Antioxidants; Atorvastatin; Disease Models, Animal; Endometriosis; Endometrium; Female; Heptanoic Acids; Pyrroles; Rats; Rats, Wistar | 2010 |
Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice.
Topics: Animals; Apoptosis; Atorvastatin; Colonic Neoplasms; Colonic Polyps; Disease Models, Animal; DNA Fragmentation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Marrow-derived MSCs and atorvastatin improve cardiac function in rat model of AMI.
Topics: Animals; Atorvastatin; Bone Marrow; Combined Modality Therapy; Disease Models, Animal; Heptanoic Acids; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ventricular Function | 2011 |
Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Anticholesteremic Agents; Arachidonate 5-Lipoxygenase; Atorvastatin; Carotid Stenosis; Carrier Proteins; Disease Models, Animal; Elastic Tissue; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heptanoic Acids; Leukotriene D4; Lipids; Lipoxins; Membrane Proteins; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Receptors, Leukotriene; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tunica Intima | 2010 |
Atorvastatin reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation.
Topics: Animals; Antioxidants; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glutathione; Heptanoic Acids; Ischemia; Lipid Peroxidation; Ovary; Peroxidase; Pyrroles; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase | 2010 |
Effect of atorvastatin on dendritic cells of tubulointerstitium in diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Movement; Dendritic Cells; Diabetes Mellitus, Experimental; Disease Models, Animal; Heptanoic Acids; Nephritis, Interstitial; P-Selectin; Pyrroles; Rats | 2010 |
Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats.
Topics: Animals; Atorvastatin; Disease Models, Animal; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Subarachnoid Hemorrhage; Treatment Outcome; Vasodilation; Vasospasm, Intracranial | 2010 |
The influence of atorvastatin on tendon healing: an experimental study on rabbits.
Topics: Achilles Tendon; Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Orthopedic Procedures; Pyrroles; Rabbits; Tendon Injuries; Treatment Outcome; Wound Healing | 2010 |
Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Availability; Calcium; Chemistry, Pharmaceutical; Crystallization; Disease Models, Animal; Dosage Forms; Heptanoic Acids; Hypercholesterolemia; Male; Microwaves; Polyethylene Glycols; Polymers; Pyrroles; Rats; Rats, Wistar; Solubility | 2010 |
Effect of atorvastatin on angiogenesis in degenerated intervertebral disc in rat.
Topics: Angiogenesis Inducing Agents; Animals; Atorvastatin; Biomarkers; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Intervertebral Disc; Intervertebral Disc Degeneration; Male; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Wistar; Time Factors; von Willebrand Factor | 2011 |
Effect atorvastatin on serum tumor necrosis factor alpha and interleukin-1β following acute pulmonary embolism.
Topics: Animals; Atorvastatin; Disease Models, Animal; Female; Heptanoic Acids; Interleukin-1beta; Male; Pulmonary Embolism; Pyrroles; Rabbits; Tumor Necrosis Factor-alpha | 2011 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium Channels, L-Type; Disease Models, Animal; DNA Primers; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Losartan; Male; Monocrotaline; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2010 |
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2011 |
Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extremities; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Ischemia; Male; Mice; Myoblasts; Peripheral Arterial Disease; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Pyrroles; Tumor Suppressor Protein p53; Ubiquitin; Wound Healing | 2011 |
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Connective Tissue; Disease Models, Animal; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Time Factors | 2011 |
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury | 2011 |
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.
Topics: Alzheimer Disease; Animals; Antioxidants; Atorvastatin; Brain; Cholesterol; Disease Models, Animal; Dogs; Female; Heptanoic Acids; Male; Nitroso Compounds; Oxidative Stress; Pyrroles; Random Allocation | 2011 |
Effect of Atorvastatin in radiographic density on alveolar bone loss in wistar rats.
Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Atorvastatin; Bone Density; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maxilla; Periodontitis; Pyrroles; Radiography, Dental, Digital; Rats; Rats, Wistar; Statistics, Nonparametric | 2010 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery.
Topics: Adoptive Transfer; Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Cell Adhesion; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Oxidative Stress; Pyrroles | 2011 |
Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.
Topics: Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Mice; Pyrroles; Vasculitis | 2011 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
[Effect of atorvastatin on MMP-9 and TIMP-1 levels in bronchoalveolar lavage fluid and serum of rats with bleomycin-induced pulmonary fibrosis].
Topics: Animals; Atorvastatin; Bleomycin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; Heptanoic Acids; Matrix Metalloproteinase 9; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1 | 2011 |
Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: involvement of nitric oxide.
Topics: Animals; Arginine; Atorvastatin; Cholinergic Antagonists; Disease Models, Animal; Enzyme Inhibitors; Guanidines; Heptanoic Acids; Learning Disabilities; Memory; Memory Disorders; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Scopolamine | 2011 |
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.
Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha | 2011 |
Why does atorvastatin inhibit renal crystal retention?
Topics: Animals; Atorvastatin; Calcium Oxalate; Catalase; Crystallization; Disease Models, Animal; Heptanoic Acids; Kidney; Kidney Calculi; Male; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidases; Pyrroles; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Rats, Wistar; Superoxide Dismutase; Transforming Growth Factor beta | 2011 |
Atorvastatin and pitavastatin protect cerebellar Purkinje cells in AD model mice and preserve the cytokines MCP-1 and TNF-α.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Chemokine CCL2; Disease Models, Animal; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Transgenic; Purkinje Cells; Pyrroles; Quinolines; Tumor Necrosis Factor-alpha | 2011 |
The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis.
Topics: Acute Disease; Animals; Atorvastatin; Colitis; Cytokines; Disease Models, Animal; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Mice; Mice, Inbred BALB C; Pyrroles; Th1 Cells; Th2 Cells | 2011 |
The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; Disease Models, Animal; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Simvastatin | 2011 |
Effects of dexamethasone and atorvastatin on atrial sodium current and its early tachycardia-induced electrical remodeling in rabbits.
Topics: Animals; Atorvastatin; Cardiac Pacing, Artificial; Cardiotonic Agents; Dexamethasone; Disease Models, Animal; Heart Atria; Heptanoic Acids; Membrane Potentials; Patch-Clamp Techniques; Pyrroles; Rabbits; Sodium Channels; Tachycardia | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Atorvastatin; Blood-Brain Barrier; Brain; Disease Models, Animal; Electroencephalography; Epilepsy, Temporal Lobe; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Triglycerides | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cricetinae; Disease Models, Animal; Dyslipidemias; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Malondialdehyde; Mesocricetus; Nitric Oxide; Phosphatidylcholine-Sterol O-Acyltransferase; Poloxamer; PPAR alpha; Pyrroles; RNA, Messenger; Superoxide Dismutase | 2011 |
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain.
Topics: Aldehydes; Alzheimer Disease; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition Disorders; Disease Models, Animal; Dogs; Glutathione; Heme Oxygenase-1; Heptanoic Acids; Ketocholesterols; Linear Models; Liver; Oxidative Stress; Pyrroles; Up-Regulation | 2012 |
[Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
Topics: Animals; Atorvastatin; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
Antinociception induced by atorvastatin in different pain models.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hot Temperature; Male; Mice; Pain; Pain Measurement; Pyrroles | 2011 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Blotting, Western; Cerebral Cortex; Cerebrovascular Circulation; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; Female; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunohistochemistry; Matrix Metalloproteinase 9; Mice; Mice, Transgenic; Neuroprotective Agents; Pyrroles; Quinolines | 2011 |
Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 12; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Heart Failure; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Myocardial Infarction; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Wistar; Transcription Factor CHOP | 2011 |
Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction.
Topics: Adipose Tissue; Animals; Atorvastatin; bcl-2-Associated X Protein; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Disease Models, Animal; GATA4 Transcription Factor; Heart Function Tests; Heptanoic Acids; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rats; Rats, Sprague-Dawley; Troponin I; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2011 |
Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Carotid Arteries; CD40 Antigens; Clopidogrel; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Aggregation Inhibitors; Pyrroles; Radiation Dosage; Radiation Injuries, Experimental; Random Allocation; Reference Values; Statistics, Nonparametric; Ticlopidine | 2011 |
Effects of atorvastatin on pathological changes in brain tissue and plasma MMP-9 in rats with intracerebral hemorrhage.
Topics: Animals; Atorvastatin; Brain; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Water | 2012 |
The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Male; Memory; Mice; Motor Activity; Phenytoin; Pyrroles; Seizures; Valproic Acid | 2012 |
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.
Topics: Animals; Antimalarials; Apoptosis; Atorvastatin; Brain; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Histocytochemistry; Immunohistochemistry; Malaria, Cerebral; Mefloquine; Mice; Neurons; Plasmodium berghei; Pyrroles; Survival Analysis; Treatment Outcome | 2012 |
Probucol and atorvastatin in combination protect rat brains in MCAO model: upregulating Peroxiredoxin2, Foxo3a and Nrf2 expression.
Topics: Animals; Atorvastatin; Body Fluids; Brain; Disease Models, Animal; Drug Therapy, Combination; Forkhead Box Protein O3; Forkhead Transcription Factors; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; NF-E2-Related Factor 2; Peroxiredoxins; Probucol; Pyrroles; Rats; Up-Regulation; Water | 2012 |
Protective effect of atorvastatin on bone tissue in orchidectomised male albino Wistar rats.
Topics: Animals; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Compressive Strength; Disease Models, Animal; Femur; Heptanoic Acids; Male; Orchiectomy; Osteoporosis; Pyrroles; Rats; Rats, Wistar; Tibia | 2012 |
Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
Topics: Animals; Atorvastatin; beta-Glucans; Biomarkers; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Liver; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Poloxamer; Pyrroles; Scattering, Small Angle; Time Factors; Triglycerides; X-Ray Diffraction | 2012 |
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Pyrroles; Receptors, LDL | 2012 |
Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide.
Topics: Analysis of Variance; Animals; Anticonvulsants; Atorvastatin; Convulsants; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Guanidines; Heptanoic Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pentylenetetrazole; Pyrroles; Seizures; Time Factors | 2012 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
The effect of herb-partition moxibustion on Toll-like receptor 4 in rabbit aorta during atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antigens; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Heptanoic Acids; Magnoliopsida; Moxibustion; Plant Preparations; Polymerase Chain Reaction; Pyrroles; Rabbits; Random Allocation; RNA, Messenger; Toll-Like Receptor 4 | 2012 |
Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intercellular Adhesion Molecule-1; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2013 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Reperfusion Injury; Perfusion; Pyrroles; Rats; Rats, Wistar; Time Factors; Vasodilation; Vasodilator Agents | 2013 |
Deleterious effects of high concentrations of (-)-epigallocatechin-3-gallate and atorvastatin in mice with colon inflammation.
Topics: Animals; Atorvastatin; Azoxymethane; Catechin; Colitis; Colon; Colonic Neoplasms; Dextran Sulfate; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Heptanoic Acids; Leukotriene B4; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pyrroles; Rectum; Weight Loss | 2012 |
Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Brain; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Mice; Mice, Transgenic; Plaque, Amyloid; Pyrroles; Quinolines | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Glucosamine; Heptanoic Acids; Humans; Matrix Metalloproteinase 9; Maze Learning; Methylcellulose; Mice; Mice, Transgenic; Mutation; Pyrroles; Quinolines | 2012 |
The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Enzyme Inhibitors; Epilepsy, Tonic-Clonic; Guanidines; Heptanoic Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pentylenetetrazole; Pyrroles | 2012 |
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Topics: Animals; Atorvastatin; Cell Communication; Disease Models, Animal; Endothelial Cells; Gene Expression; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Kruppel-Like Transcription Factors; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Paracrine Communication; Pyrroles; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2013 |
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Biomarkers; Collateral Circulation; Coronary Circulation; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Metabolic Syndrome; Microvessels; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Neovascularization, Physiologic; Oxidative Stress; Pyrroles; Signal Transduction; Swine; Swine, Miniature; Vasodilation; Vasodilator Agents | 2012 |
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2.
Topics: Animals; Atorvastatin; Base Sequence; Binding Sites; Blood Glucose; Cells, Cultured; Chromatin Immunoprecipitation; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Male; Mevalonic Acid; Molecular Sequence Data; Nerve Tissue Proteins; Nitric Oxide Synthase Type III; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred OLETF; RNA Interference; Time Factors; Transfection; Vasodilation; Vasodilator Agents | 2013 |
Neuroprotective effect of atorvastatin involves suppression of TNF-α and upregulation of IL-10 in a rat model of intracerebral hemorrhage.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Heptanoic Acids; Interleukin-10; Male; Microglia; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study.
Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum | 2013 |
High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Atorvastatin; Blotting, Western; Cholesterol; Cytochrome P-450 CYP3A; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Guinea Pigs; Heptanoic Acids; Liver; Pyrroles; Random Allocation | 2013 |
Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorobenzenes; Hepatic Stellate Cells; Heptanoic Acids; Hypertension, Portal; In Vitro Techniques; Incidence; Injections; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Thioacetamide | 2013 |
Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Hippocampus; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Cholesterol; Disease Models, Animal; Drug Synergism; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles; Spectrum Analysis, Raman | 2002 |
Withdrawal of statin treatment abrogates stroke protection in mice.
Topics: Animals; Aorta; Atorvastatin; Bleeding Time; Blood Coagulation; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Stroke; Substance Withdrawal Syndrome; Vena Cava, Inferior; Venous Thrombosis | 2003 |
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyrroles; Reperfusion; Signal Transduction; Time Factors; Up-Regulation | 2003 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Disease Models, Animal; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Oxazepines; Piperidines; Pyrroles; Rabbits; Receptors, LDL; Simvastatin; Species Specificity; Time Factors; Triglycerides | 2003 |
Pretreatment with statins enhances myocardial protection during coronary revascularization.
Topics: Animals; Atorvastatin; Cardiopulmonary Bypass; Disease Models, Animal; Electric Countershock; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Ischemia; Myocardial Revascularization; Premedication; Pyrroles; Random Allocation; Swine | 2003 |
Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Glucose; Glucose Tolerance Test; Heptanoic Acids; Injections, Intravenous; Insulin; Insulin Secretion; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors | 2003 |
Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury.
Topics: Administration, Oral; Animals; Atorvastatin; Brain; Brain Injuries; Cell Survival; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Male; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Synapses; Synaptophysin | 2004 |
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
Topics: Animals; Atorvastatin; Brain; Cerebral Hemorrhage; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nervous System; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Severity of Illness Index; Treatment Outcome | 2004 |
Is it time for medical therapy for aortic valve disease?
Topics: Aged; Aged, 80 and over; Animals; Aortic Valve Stenosis; Atorvastatin; Biopsy, Needle; Calcinosis; Controlled Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunohistochemistry; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Nuclear Proteins; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Trans-Activators; Treatment Outcome | 2004 |
Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Female; Gliosis; Heptanoic Acids; Interleukin-1; Motor Activity; Myelitis; Necrosis; Nerve Degeneration; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oligodendroglia; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Spinal Cord; Spinal Cord Injuries; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
Delayed thrombosis after traumatic brain injury in rats.
Topics: Animals; Atorvastatin; Blood Coagulation Factors; Brain; Brain Injuries; Disease Models, Animal; Fibrin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Thrombosis; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2004 |
Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Atorvastatin; Blood Pressure; Body Weight; Deoxyguanosine; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Infarction, Middle Cerebral Artery; Lipids; Lysine; Oxidative Stress; Pyrroles; Quinolines; Rats; Rats, Inbred SHR; Simvastatin; Survival Analysis | 2005 |
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator | 2005 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Cardiomyopathy, Hypertrophic; Cholesterol; Disease Models, Animal; DNA, Mitochondrial; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Myosin Heavy Chains; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Rabbits; Ventricular Function, Left | 2005 |
Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hypercholesterolemia; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2005 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor | 2006 |
Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats.
Topics: Adoptive Transfer; Animals; Atorvastatin; Autoimmune Diseases; Disease Models, Animal; Echocardiography; Enzyme-Linked Immunosorbent Assay; Genes, MHC Class II; Heptanoic Acids; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocarditis; Myocardium; Myocytes, Cardiac; Nuclear Proteins; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred Lew; RNA, Messenger; T-Lymphocytes; Th2 Cells; Trans-Activators | 2006 |
Atorvastatin and glatiramer acetate: new hope in MS?
Topics: Adjuvants, Immunologic; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Glatiramer Acetate; Heptanoic Acids; Humans; Immunotherapy; Inflammation; Multiple Sclerosis; Peptides; Pyrroles | 2006 |
Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.
Topics: Animals; Atorvastatin; Cerebral Infarction; Disease Models, Animal; Heptanoic Acids; Male; NADPH Oxidases; Neuroprotective Agents; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Time Factors | 2006 |
Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
Topics: Analysis of Variance; Animals; Atorvastatin; Biomarkers; Blood Pressure; Body Weight; Dexamethasone; Disease Models, Animal; Down-Regulation; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thymus Gland | 2006 |
Intracellular retention of hepatic serpins caused by severe hyperlipidemia.
Topics: Animals; Antithrombins; Atorvastatin; Chickens; Dietary Fats; Disease Models, Animal; Factor Xa Inhibitors; Fatty Liver; Heparin Cofactor II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intracellular Fluid; Lipid Metabolism; Lipids; Liver; Male; Pyrroles; Serpins | 2006 |
Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9.
Topics: Acute Disease; Analysis of Variance; Animals; Atorvastatin; Disease Models, Animal; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Injections, Intravenous; Luminescence; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microspheres; Nitrates; Nitrites; Proportional Hazards Models; Pulmonary Embolism; Pulmonary Wedge Pressure; Pyrroles; Random Allocation; Rats; Rats, Wistar; Survival Rate | 2007 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Disease Models, Animal; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; P-Selectin; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Ticlopidine; Vascular Cell Adhesion Molecule-1 | 2007 |
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2007 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Atorvastatin; Autoimmune Diseases; Disease Models, Animal; Heart; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Tumor Necrosis Factor-alpha; Ventricular Function | 2007 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
High-dose atorvastatin causes regression of endometriotic implants: a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Female; Heptanoic Acids; Leuprolide; Pyrroles; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2007 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Movement; Chemokine CCL2; Choroidal Neovascularization; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Laser Coagulation; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrroles; Vascular Endothelial Growth Factor A | 2007 |
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Edema; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Chemotaxis, Leukocyte; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Pyrroles; Recovery of Function; RNA, Messenger; Simvastatin; Treatment Outcome | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.
Topics: Animals; Atorvastatin; Biosynthetic Pathways; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Early Growth Response Protein 1; Fibrinolytic Agents; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A | 2007 |
Atorvastatin and portal pressure.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver Cirrhosis; Pyrroles; Rats | 2007 |
Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
Topics: Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mitochondria; Nerve Degeneration; Neurotoxins; Nitric Oxide Synthase Type II; Nitro Compounds; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley | 2008 |
Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Drug Delivery Systems; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pyrroles; Tissue Distribution | 2007 |
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Topics: Animals; Atorvastatin; Biopterins; Body Weight; Cell Adhesion Molecules; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Male; Microfilament Proteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pyrroles; Rats; Rats, Wistar; Stem Cells; Tetrahydrofolate Dehydrogenase; Vasodilation | 2008 |
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Disease Models, Animal; Heptanoic Acids; Homeodomain Proteins; Male; Middle Cerebral Artery; Neurons; Presenilin-1; Pyrroles; Rats; Rats, Wistar; Receptor, Notch1; Signal Transduction; Stem Cells; Stroke; Transcription Factor HES-1 | 2008 |
[Effects of atorvastatin on expression of peroxisome proliferation activated receptor gamma in unilateral ureteral obstruction in rats].
Topics: Animals; Atorvastatin; Disease Models, Animal; Female; Heptanoic Acids; Kidney Tubules; Nephrosclerosis; PPAR gamma; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2007 |
Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lactic Acid; Lipids; Male; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis.
Topics: Animals; Apolipoprotein A-I; Atorvastatin; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Mice; Occult Blood; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2008 |
[Cardioprotective effects of atorvastatin preconditioning via iNOS upregulation in a rabbit ischemia/reperfusion model].
Topics: Animals; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Ischemic Preconditioning, Myocardial; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type II; Potassium Channels; Pyrroles; Rabbits; Up-Regulation | 2007 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blotting, Western; Chemokine CCL2; Diet, Atherogenic; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Mice; Mice, Knockout; Myocardium; Pyrroles; Receptors, LDL | 2008 |
Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Lipids; Male; Myocardium; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reproducibility of Results; RNA, Messenger; Time Factors | 2008 |
Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
Topics: Acute-Phase Proteins; Alanine Transaminase; Animals; Atorvastatin; Carrier Proteins; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Endotoxins; Fatty Liver; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-1beta; Lipids; Lipopolysaccharide Receptors; Liver; Lymphocyte Antigen 96; Male; Membrane Glycoproteins; NF-kappa B; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; RNA, Messenger; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2008 |
Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Pressure; Caffeine; Coffee; Disease Models, Animal; Food-Drug Interactions; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1 | 2008 |
Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells.
Topics: Analysis of Variance; Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cells, Cultured; Disease Models, Animal; Fas Ligand Protein; Female; Flow Cytometry; Hepatocytes; Heptanoic Acids; JNK Mitogen-Activated Protein Kinases; Male; Microscopy, Confocal; NF-kappa B; Probability; Pyrroles; Rats; Rats, Wistar; Sensitivity and Specificity | 2008 |
Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cytokines; Disease Models, Animal; Down-Regulation; Endotoxemia; Female; Heart; Heptanoic Acids; Inflammation Mediators; Kidney; Leukocytes; Lipopolysaccharides; Myocardium; Organ Specificity; Pyrroles; Random Allocation; Swine; Up-Regulation | 2008 |
Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
Topics: Animals; Atorvastatin; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-10; Macrophages; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Atorvastatin; Cyclooxygenase 2; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptides; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tyrphostins; Up-Regulation | 2008 |
Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration.
Topics: Animals; Anticholesteremic Agents; Aortic Aneurysm, Abdominal; Atorvastatin; Cell Movement; Collagen; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Pancreatic Elastase; Pyrroles; Rats; Rats, Wistar; Treatment Outcome | 2009 |
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Topics: Animals; Atorvastatin; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Evaluation Studies as Topic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation; Tunica Intima | 1998 |
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima | 1999 |
Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Culture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Injections, Intraperitoneal; Liver; Mice; Mice, Inbred C57BL; Poloxamer; Pyrroles; Reference Values; Remission Induction; Triglycerides | 2000 |
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hypercholesterolemia; Kidney; Male; Nitroprusside; Oxazoles; Phenylephrine; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Renal Circulation; Vasodilation | 2001 |
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Isoenzymes; Lipids; Macrophages; Male; Matrix Metalloproteinases; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrroles; Rabbits; Random Allocation; Randomized Controlled Trials as Topic; Time Factors | 2002 |
Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Coenzyme A Ligases; Dietary Sucrose; Disease Models, Animal; Down-Regulation; Fatty Acids, Nonesterified; Heptanoic Acids; Hypertriglyceridemia; Lipase; Lipoproteins, VLDL; Liver; Male; Oleic Acid; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides; Tritium | 2002 |
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic ins
Topics: Animals; Apolipoproteins B; Atorvastatin; Blood Glucose; Cells, Cultured; Cholesterol; Cricetinae; Disease Models, Animal; Fructose; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Liver; Luminescent Measurements; Mesocricetus; Phosphorylation; Pyrroles; Receptor, Insulin; Triglycerides | 2002 |
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.
Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Cell Division; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Macrophages; Male; Microscopy, Immunoelectron; Osteoblasts; Osteopontin; Proliferating Cell Nuclear Antigen; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sialoglycoproteins | 2002 |